# 2026年1月21日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 动态ctDNA监测指导接受新辅助化疗的局部晚期直肠癌患者的早期治疗强化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556959)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41556959
**DOI：** 10.1158/1078-0432.CCR-25-3774

### 第一部分 原文与翻译

**英文原标题：** Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy.

> **英文摘要：**
> PURPOSE: Neoadjuvant chemotherapy (NCT) has been accepted as the standard management for locally advanced rectal cancer (LARC) without high-risk factors. However, many patients experience poor pathological response, necessitating early prediction tools. We investigated dynamic circulating tumor DNA (ctDNA) analysis for early response monitoring in LARC patients undergoing NCT. EXPERIMENTAL DESIGN: In this biomarker substudy of the multicenter randomized COPEC trial, 153 patients with low-/intermediate-risk LARC were enrolled. Plasma samples (n=526) were collected at baseline and after each cycle of NCT. ctDNA was analyzed via tumor-informed sequencing. Patients were classified by dynamic status into high-risk (delayed/no clearance, recurred positive) and low-risk (early clearance, persistent negative) groups. Poor response was defined as pathological tumor regression grade (pTRG) 3 or distant metastasis. The association between ctDNA status and responses was analyzed. RESULTS: No patient with high-risk ctDNA dynamics achieved a major pathological response (pTRG 0-1). The poor response rate was 59.4% in the high-risk group versus 12.4% in the low-risk group (p<0.001). High-risk dynamic ctDNA status was a strong independent predictor of poor response (odds ratio [OR]=11.69, 95% CI 5.00-27.25, p<0.001). Both delayed/no clearance (OR=12.64, p<0.001) and recurred positivity (OR=8.91, p<0.001) were significant risk factors. A single preoperative ctDNA-positive result also predicted poor response (OR=11.27, p <0.001). CONCLUSIONS: Dynamic ctDNA monitoring identifies LARC patients at high risk for NCT failure as early as two cycles into treatment, which can form the basis for an adaptive trial design and eventual personalization of therapy selection.

> **中文摘要：**
> 目的：新辅助化疗（NCT）已被接受为无高危因素的局部晚期直肠癌（LARC）的标准管理方案。然而，许多患者的病理缓解情况不佳，因此需要早期预测工具。我们研究了动态循环肿瘤DNA（ctDNA）分析在接受新辅助化疗的局部晚期直肠癌患者早期反应监测中的应用。实验设计：在这项多中心随机COPEC试验的生物标志物子研究中，共纳入了153名低/中危局部晚期直肠癌患者。在基线和每个新辅助化疗周期后采集了血浆样本（n=526）。通过肿瘤知情测序分析了ctDNA。根据动态状态将患者分为高危组（延迟/未清除、再次转阳）和低危组（早期清除、持续阴性）。反应差定义为病理肿瘤退缩分级（pTRG）为3级或发生远处转移。分析了ctDNA状态与反应之间的关联。结果：动态ctDNA高危组中没有患者达到主要病理缓解（pTRG 0-1）。高危组的反应差率为59.4%，而低危组为12.4%（p<0.001）。高危动态ctDNA状态是反应差的强独立预测因子（比值比[OR]=11.69，95% CI 5.00-27.25，p<0.001）。延迟/未清除（OR=12.64，p<0.001）和再次转阳（OR=8.91，p<0.001）均为显著危险因素。单次术前ctDNA阳性结果也能预测反应差（OR=11.27，p <0.001）。结论：动态ctDNA监测早在治疗两个周期时即可识别出新辅助化疗失败风险极高的局部晚期直肠癌患者，这可为适应性试验设计及最终的个体化治疗选择提供依据。

### 第二部分 AI 大师评价

该研究基于多中心随机COPEC试验，深入探讨了动态ctDNA监测在局部晚期直肠癌新辅助化疗疗效预测中的临床价值。通过精细化的动态分类（如延迟清除、再次转阳等），研究证实了高危ctDNA状态是病理反应差的强独立预测因子，且早在治疗两周期后即可实现精准识别。这一发现不仅为直肠癌的个体化治疗和早期治疗强化提供了可靠的分子证据，也为未来基于生物标志物的适应性临床试验设计指明了方向。

---

## 2. 克唑替尼治疗MET扩增或14号外显子缺失肿瘤患者：NCI-MATCH ECOG-ACRIN试验（EAY131）子方案C1和C2的结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556942)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41556942
**DOI：** 10.1158/1078-0432.CCR-25-1247

### 第一部分 原文与翻译

**英文原标题：** Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.

> **英文摘要：**
> BACKGROUND: The NCI-MATCH trial enrolled patients to subprotocols C1 and C2 to evaluate the METtyrosine kinase inhibitor crizotinib for efficacy in patients with MET amplification (METamp; C1) or MET exon 14 skipping mutation (METex14; C2). METHODS: Tumors harboring METamp or METex14 were confirmed by Oncomine assay, RNA-sequencing, and Anchored Multiplex PCR. Patients received 250 mg crizotinib orally daily until disease progression or unacceptable toxicity. Primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS), 6-month PFS, and overall survival (OS). RESULTS: C1 efficacy analysis comprised 28 of 44 enrolled patients (17 gastrointestinal, 7 lung, 4 other tumor types). Four patients had a partial response (PR), 10 had stable disease (SD), 13 had progressive disease (PD); one unevaluable. ORR was 14% (4/28, 90%; CI 5.0-29.8%). Median (m) PFS was 3.4 months (90% CI 1.8-3.7), mOS 7.1 months (90% CI 5.0-11.5). C2 included 14 of 20 patients (5 gastrointestinal, 6 lung, 3 other). Two patients had PR, 4 SD (2 >6 months), and 4 PD were observed. ORR was 14% (2/14, 90% CI 2.6-38.5%). mPFS and mOS were 2.0 months (90% CI 1.4-4.1) and 10.2 months (90% CI 2.3-19.6).METex14 cases with read count ≥50,000 had mPFS 8.8 months (90% CI 2.1-NA) versus 1.7 months (90% CI 1.1-3.7). CONCLUSION: Crizotinib demonstrated clinical activity across tumors with METamp and METex14.Subprotocol C1, but not C2, met its primary endpoint. In METex14 disease, a read count cutoff >50,000 may help distinguish true pathogenic variants from low-level splice transcripts and enable more accurate classification.

> **中文摘要：**
> 背景：NCI-MATCH试验将患者纳入子方案C1和C2，以评估MET酪氨酸激酶抑制剂克唑替尼对MET扩增（METamp；C1）或MET 14号外显子跳跃突变（METex14；C2）患者的疗效。方法：通过Oncomine检测、RNA测序和锚定多重PCR确认携带METamp或METex14的肿瘤。患者每日口服250 mg克唑替尼，直至疾病进展或出现不可接受的毒性。主要终点为客观缓解率（ORR）；次要终点包括无进展生存期（PFS）、6个月PFS率和总生存期（OS）。结果：C1方案的疗效分析包含44名入组患者中的28名（17例胃肠道肿瘤、7例肺癌、4例其他肿瘤类型）。4例患者达到部分缓解（PR），10例为疾病稳定（SD），13例为疾病进展（PD）；1例无法评估。ORR为14%（4/28，90% CI 5.0-29.8%）。中位（m）PFS为3.4个月（90% CI 1.8-3.7），mOS为7.1个月（90% CI 5.0-11.5）。C2方案包括20名患者中的14名（5例胃肠道肿瘤、6例肺癌、3例其他）。观察到2例PR，4例SD（其中2例>6个月）和4例PD。ORR为14%（2/14，90% CI 2.6-38.5%）。mPFS和mOS分别为2.0个月（90% CI 1.4-4.1）和10.2个月（90% CI 2.3-19.6）。在METex14病例中，读数计数（read count）≥50,000的患者mPFS为8.8个月（90% CI 2.1-NA），而读数较低者仅为1.7个月（90% CI 1.1-3.7）。结论：克唑替尼在携带METamp和METex14的多种肿瘤中均显示出临床活性。子方案C1达到了其主要终点，而C2未达到。在METex14疾病中，设置>50,000的读数计数切点可能有助于区分真正的致病性变异与低水平剪接转录本，从而实现更准确的分类。

### 第二部分 AI 大师评价

本研究基于NCI-MATCH“篮子试验”平台，证实了克唑替尼在跨瘤种的MET扩增及METex14突变患者中具有明确的抗肿瘤活性。研究发现MET扩增组（C1）达到了预设的主要终点，而METex14组（C2）虽有获益但未达标，提示不同MET变异类型的响应存在差异。最具临床价值的发现是提出了METex14检测中读数计数（read count）的阈值（50,000）可作为预测疗效的关键生物标志物，这为分子诊断的规范化和精准治疗的筛选提供了重要的工程化数据支持。

---

## 3. MHC“组合拳”出击，重创癌症

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556940)
**期刊：** The Journal of experimental medicine
**PMID：** 41556940
**DOI：** 10.1084/jem.20252203

### 第一部分 原文与翻译

**英文原标题：** MHC one-two punch knocks out cancer.

> **英文摘要：**
> In this issue of JEM, Zhang et al. (https://doi.org/10.1084/jem.20250025) describe complete T cell antigens (CTAs), comprised of class I and class II immunogenic peptides fused in a single polypeptide that greatly increase the effectiveness of cancer immunotherapy, even when the CTA antigens are not expressed in tumor cells.

> **中文摘要：**
> 在本期《实验医学杂志》（JEM）中，Zhang等人（https://doi.org/10.1084/jem.20250025）描述了完整T细胞抗原（CTAs）。这种抗原由融合在单一多肽中的I类和II类免疫原性肽组成，能够显著增强癌症免疫治疗的有效性，甚至在肿瘤细胞不表达CTA抗原的情况下也是如此。

### 第二部分 AI 大师评价

本文评述了Zhang等人在肿瘤疫苗领域的突破性研究，核心介绍了“完整T细胞抗原（CTA）”这一创新概念。该方案通过将MHC I类和II类限制性肽融合，实现了CD8+和CD4+ T细胞的协同激活，通过免疫“组合拳”显著提升了治疗效果。其最重要的发现是，即便肿瘤细胞不表达相关抗原，该系统仍能通过增强免疫微环境发挥抗癌作用，为开发普适性更强的免疫治疗策略提供了新思路。

---

## 4. MLH1林奇综合征结直肠癌由异质性Wnt通路基因突变驱动

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556860)
**期刊：** Gastroenterology
**PMID：** 41556860
**DOI：** 10.1053/j.gastro.2025.10.012

### 第一部分 原文与翻译

**英文原标题：** MLH1 Lynch Syndrome Colorectal Cancers Are Driven by Heterogeneous Wnt Pathway Gene Mutations.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究揭示了MLH1型林奇综合征（Lynch Syndrome）相关结直肠癌在分子水平上的独特特征，重点阐述了Wnt信号通路基因突变的高度异质性。研究表明，此类肿瘤的发生并非仅由单一的典型驱动因子主导，而是涉及多样化的基因组变异。这一发现挑战了对该病理类型肿瘤演化模式的传统认知，为理解错配修复缺陷型结直肠癌的生物学复杂性以及优化精准诊疗策略提供了关键证据。

---

## 5. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 6. HLA杂合性影响结直肠癌风险及生存预后

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556857)
**期刊：** Gastroenterology
**PMID：** 41556857
**DOI：** 10.1053/j.gastro.2025.10.020

### 第一部分 原文与翻译

**英文原标题：** HLA Heterozygosity Influences Colorectal Cancer Risk and Survival Outcome.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究探讨了人类白细胞抗原（HLA）杂合性在结直肠癌发病风险及生存预后中的关键作用。HLA多样性通常被认为与更广谱的抗原呈递能力相关，杂合性的缺失可能削弱免疫系统对肿瘤新抗原的监控，从而驱动肿瘤演变。这项研究在免疫遗传学层面为结直肠癌的风险分层提供了重要证据，并对理解肿瘤免疫逃逸机制具有显著的学术价值。

---

## 7. 血清生物标志物联合超声在高风险患者肝细胞癌早期检测中的应用价值：一项随机对照试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556856)
**期刊：** Gastroenterology
**PMID：** 41556856
**DOI：** 10.1053/j.gastro.2025.09.010

### 第一部分 原文与翻译

**英文原标题：** Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.

> **英文摘要：**
> BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) surveillance is key to early diagnosis and timely curative treatment. Current strategies are suboptimal with many patients presenting with advanced HCC. This randomized controlled trial compared the combined use of serum biomarker (BM) measurements and abdominal ultrasound (US) with US alone for the diagnosis of early-stage HCC. METHODS: Adults with cirrhosis or high-risk hepatitis B virus (HBV) infection were randomized (1:1) to biannual surveillance with US alone (group A) or US and BMs (group B) in blocks of 2 or 4. Positive US results or elevated BMs (α-fetoprotein [AFP] >100 ng/mL, lectin-reactive fraction of AFP [AFP-L3] >10%, des-gamma-carboxy prothrombin [DCP] >2 ng/mL) triggered further imaging for HCC confirmation. Primary end point was proportion of early-stage HCCs. RESULTS: There were 1208 patients randomized (n = 603 group A, n = 605 group B). Mean ± SD age was 58.4 ± 9.8 years, 71.8% were male, 55.1% were Asian, 64.0% had HBV, and 64.3% had cirrhosis. During follow-up, 35 HCCs (5.8%) developed in group A (n = 30 early-stage, n = 5 late-stage) and 27 (4.5%) developed in group B (n = 22 early-stage, n = 5 late-stage). Early-stage HCC incidence was 1.2 per 100 person-years with cumulative probabilities of 1.3% at 52 weeks and 5.9% at 260 weeks. Early-stage HCC detection rate did not differ by study arm (hazard ratio, 0.81; 95% CI, 0.47-1.40; P = .45). In group B, elevated AFP-L3 was equally effective compared with using all 3 BMs. CONCLUSIONS: Addition of AFP, AFP-L3, and DCP to biannual US did not improve early-stage HCC detection. The trial was not adequately powered to provide evidence that the use of BMs aside from US plus AFP improves HCC surveillance. Establishing and validating alternative approaches to incorporation of BMs may improve surveillance methods for early-stage HCC detection.

> **中文摘要：**
> 背景与目的：肝细胞癌（HCC）监测是实现早期诊断和及时根治性治疗的关键。目前的监测策略并不理想，许多患者确诊时已处于晚期。本随机对照试验比较了联合应用血清生物标志物（BM）测定与腹部超声（US）相对单独应用US诊断早期HCC的效果。方法：将患有肝硬化或高风险乙型肝炎病毒（HBV）感染的成人按2或4个区块随机（1:1）分配至每半年一次的单独US监测组（A组）或US联合BM监测组（B组）。超声结果阳性或BM升高（甲胎蛋白 [AFP] >100 ng/mL，甲胎蛋白异质体 [AFP-L3] >10%，异常凝血酶原 [DCP] >2 ng/mL）将触发进一步的影像学检查以确认HCC。主要终点是早期HCC的比例。结果：共纳入1208名随机分配的患者（A组603人，B组605人）。平均年龄为58.4 ± 9.8岁，71.8%为男性，55.1%为亚洲人，64.0%患有HBV，64.3%患有肝硬化。随访期间，A组发生35例HCC（5.8%）（其中30例为早期，5例为晚期），B组发生27例HCC（4.5%）（其中22例为早期，5例为晚期）。早期HCC的发病率为每100人年1.2例，52周时的累积概率为1.3%，260周时为5.9%。早期HCC检出率在两组间无显著差异（风险比 0.81；95% CI，0.47-1.40；P = 0.45）。在B组中，AFP-L3升高在检出效能上与同时使用三种BM相当。结论：在每半年一次的超声检查基础上增加AFP、AFP-L3和DCP并不能改善早期HCC的检出。本试验的效能不足以证明在US联合AFP之外使用其他BM能改善HCC监测。建立并验证将BM纳入监测的其他替代方法可能会改善早期HCC的检测水平。

### 第二部分 AI 大师评价

本研究是一项针对高风险人群肝癌早期筛查的高质量随机对照试验。研究核心在于探讨在传统超声筛查基础上增加三项血清标志物（AFP、AFP-L3、DCP）能否提升早期诊断效能，结果显示多标志物联合方案并未在检出率上表现出统计学优势。这一发现反映出目前生物标志物在临床应用中的瓶颈，同时也由于样本效能的局限，提示未来需探索更精准的生物标志物组合方式。该研究为临床决策提供了重要的阴性证据，强调了单纯增加检测项目未必能改善早期诊断预后。

---

## 8. KRASG12R突变型胰腺癌具有受限的ERK/MAPK转录活性和独特的肿瘤微环境特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556816)
**期刊：** Cancer research
**PMID：** 41556816
**DOI：** 10.1158/0008-5472.CAN-25-2630

### 第一部分 原文与翻译

**英文原标题：** KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.

> **英文摘要：**
> Patients with pancreatic ductal adenocarcinoma (PDAC) harboring KRASG12R mutations have increased overall survival relative to patients with KRASG12D/V mutations. To investigate the mechanisms underlying this differential outcome, we developed a genetically engineered mouse model (GEMM) harboring KRASG12R and p53R172H mutations (KrasLSL-G12R/+;Trp53LSL-R172H/+;p48Cre-ERTM). Unlike KRASG12D models, KRASG12R-GEMMs exhibited limited tumorigenesis, with only 10% developing pancreatic tumors after one year. Additionally, mice harboring whole-body expression of KRASG12R remained healthy for over one year, whereas KRASG12D mice developed rapid multifocal disease. Comparison of KRAS mutant-selective transcription and signaling in murine and human PDAC cell lines, GEMMs, and patient-derived xenograft mouse models revealed that direct KRAS-mediated PI3K activation is necessary for robust tumor initiation in GEMMs. Unexpectedly, KRAS was not the primary driver of PI3K activity in human PDAC cell lines and patient-derived xenograft models regardless of KRAS mutation. KRASG12R and KRASG12D activated a similar pancreas-specific transcriptional network, but KRASG12R promoted these pathways less robustly due to limited ERK/MAPK nuclear translocation. Finally, KRASG12R human pancreatic tumors had an altered tumor microenvironment (TME) with reduced collagen deposition and metastatic liver invasion. Together, this study demonstrated that KRASG12R is capable of driving tumorigenesis despite the reduced ERK/MAPK nuclear translocation and transcriptional output. Although human KRASG12D and KRASG12R-mutant tumors display unexpected similarities in PI3K activity, the differential ERK/MAPK signaling activity and the extrinsic consequences on the TME provide support for using KRASG12R mutation status as a prognostic biomarker for therapeutic strategies.

> **中文摘要：**
> 携带KRASG12R突变的胰腺导管腺癌（PDAC）患者相对于携带KRASG12D/V突变的患者，其总生存期有所增加。为了研究这种差异化预后的潜在机制，我们开发了一种携带KRASG12R和p53R172H突变的基因工程小鼠模型（GEMM）（KrasLSL-G12R/+；Trp53LSL-R172H/+；p48Cre-ERTM）。与KRASG12D模型不同，KRASG12R-GEMMs表现出受限的肿瘤发生能力，一年后仅有10%的小鼠发展为胰腺肿瘤。此外，全身表达KRASG12R的小鼠保持健康超过一年，而KRASG12D小鼠则迅速发展为多灶性疾病。通过比较小鼠和人类PDAC细胞系、GEMMs以及患者来源的异种移植（PDX）小鼠模型中KRAS突变选择性的转录和信号传导，研究发现直接由KRAS介导的PI3K激活对于GEMMs中强劲的肿瘤启动是必要的。出乎意料的是，无论KRAS突变情况如何，KRAS并不是人类PDAC细胞系和PDX模型中PI3K活性的主要驱动因素。KRASG12R和KRASG12D激活了类似的胰腺特异性转录网络，但由于ERK/MAPK核易位受限，KRASG12R对这些通路的正向促进作用较弱。最后，KRASG12R突变的人类胰腺肿瘤具有改变的肿瘤微环境（TME），表现为胶原沉积减少和肝转移侵袭减弱。总之，本研究证明尽管ERK/MAPK核易位和转录输出有所减少，KRASG12R仍能够驱动肿瘤发生。虽然人类KRASG12D和KRASG12R突变肿瘤在PI3K活性方面表现出意想不到的相似性，但差异化的ERK/MAPK信号活性及其对TME的外源性影响，为将KRASG12R突变状态作为治疗策略的预后生物标志物提供了支持。

### 第二部分 AI 大师评价

本研究通过构建新型基因工程小鼠模型，深入探讨了KRASG12R突变型胰腺癌预后优于G12D/V亚型的分子机制。研究发现，尽管KRASG12R具备致癌潜能，但其ERK/MAPK信号的核易位受限导致转录输出强度降低，并伴随肿瘤微环境中胶原沉积减少和转移侵袭力下降。该成果揭示了不同KRAS突变位点在信号转导与微环境塑造上的显著异质性，为胰腺癌的精准预后评估及亚型特异性治疗策略开发提供了重要理论依据。

---

## 9. 胰腺导管腺癌预后评估与 CA19-9 拦截的病理组学特征：一项真实世界、多中心研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556438)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41556438
**DOI：** 10.1002/advs.202515952

### 第一部分 原文与翻译

**英文原标题：** Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study.

> **英文摘要：**
> Histopathological hematoxylin and eosin (H&E) slides contain valuable prognostic information for pancreatic ductal adenocarcinoma (PDAC), yet systematic feature extraction remains challenging. This multi-center study developed and validated an automated prognostic model using deep learning on digitized whole-slide images from 873 PDAC patients with surgical resection across three academic centers. The CrossFormer architecture achieved superior performance in external validation (area under the curve [AUC] = 0.774), significantly outperforming ResNet-18 (AUC = 0.716), ResNet-50 (AUC = 0.737), and DenseNet-121 (AUC = 0.729). Gradient-weighted Class Activation Mapping identified key prognostic features including desmoplastic stroma, high nuclear-to-cytoplasmic ratio, tumor necrosis, and immune cell infiltration. The pathomics signature effectively stratified patients into low-risk and high-risk groups with significant survival differences (p < 0.001). Critically, carbohydrate antigen 19-9 (CA19-9) retained prognostic value only in low-risk patients (hazard ratio [HR] = 2.70, p < 0.001) but not in high-risk patients (HR = 0.998, p = 0.990). High-risk patients derived substantial benefit from adjuvant chemotherapy (HR = 0.56, p = 0.038), whereas low-risk patients showed no significant benefit (HR = 0.83, p = 0.562). These findings provide actionable clinical insights: treatment intensification for high-risk patients and CA19-9-guided monitoring for low-risk patients. This validated, interpretable model transforms routine H&E slides into quantitative prognostic tools, enabling personalized treatment strategies without additional testing costs.

> **中文摘要：**
> 组织病理学苏木精-伊红（H&E）切片包含胰腺导管腺癌（PDAC）的重要预后信息，但系统的特征提取仍具有挑战性。这项多中心研究利用深度学习技术，对来自三家学术中心的 873 名接受手术切除的 PDAC 患者的数字化全切片图像进行分析，开发并验证了一个自动预后模型。CrossFormer 架构在外部验证中表现优异（曲线下面积 [AUC] = 0.774），显著优于 ResNet-18 (AUC = 0.716)、ResNet-50 (AUC = 0.737) 和 DenseNet-121 (AUC = 0.729)。梯度加权类激活映射（Grad-CAM）识别出了关键预后特征，包括促结缔组织增生性间质、高核胞浆比、肿瘤坏死和免疫细胞浸润。该病理组学特征能有效将患者分为低风险组和高风险组，两组间的生存差异具有统计学意义（p < 0.001）。至关重要的是，糖类抗原 19-9 (CA19-9) 仅在低风险患者中保留预后价值（风险比 [HR] = 2.70，p < 0.001），而在高风险患者中则无此价值（HR = 0.998，p = 0.990）。高风险患者从辅助化疗中显著获益（HR = 0.56，p = 0.038），而低风险患者未显示出显著获益（HR = 0.83，p = 0.562）。这些发现提供了具有操作性的临床见解：对高风险患者进行强化治疗，对低风险患者进行 CA19-9 引导的监测。这种经过验证且具有可解释性的模型将常规 H&E 切片转化为定量的预后工具，在不增加额外检测成本的情况下实现了个性化治疗策略。

### 第二部分 AI 大师评价

本研究利用先进的 CrossFormer 深度学习架构，开发并验证了一种基于常规 H&E 切片的 PDAC 病理组学模型，其预测效能显著优于传统卷积神经网络。研究的创新之处在于揭示了病理风险分层对 CA19-9 预后价值的“拦截”效应，并精准识别了能从辅助化疗中获益的高风险人群。该模型不仅具有良好的可解释性，且无需额外检测成本，为胰腺癌的临床决策和精准治疗提供了强有力的数字化工具。

---

## 10. 将DNA-LNPs靶向内皮细胞可提高表达强度、持续时间和特异性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556437)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41556437
**DOI：** 10.1002/advs.202515480

### 第一部分 原文与翻译

**英文原标题：** Targeting DNA-LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity.

> **英文摘要：**
> DNA-lipid nanoparticles (DNA-LNPs) loaded with inhibitors of the cGAS-STING pathway enable safe and effective delivery of DNA in vivo. Herein, we report the first instances of extrahepatic DNA-LNP targeting. DNA-LNPs conjugated to antibodies against PECAM-1 or VCAM-1 target the endothelium of the lungs and brain/spleen, respectively. These LNPs drive robust transgene expression in their target organs, with greater magnitude and duration than untargeted LNPs. Lung specificity of PECAM-targeted transgene expression increases over two weeks, resulting in markedly higher lung-to-liver expression ratios than our previous PECAM-targeted mRNA-LNPs. Off-target liver DNA expression declines to undetectable levels but persists in the lungs, while mRNA expression uniformly decreases due to its short half-life. We further improve this expression specificity by replacing full-length antibodies with Fab fragments. Single-cell analysis reveals a key mechanism underlying the improvements in organ-specificity: target organ expression is dominated by long-lived endothelial cells, while off-target liver delivery and expression are in non-endothelial cells with shorter half-lives. Collectively, these studies demonstrate that targeted DNA-LNPs achieve high levels of organ- and cell-type-specific transgene expression and thus provide a therapeutic platform for dozens of endothelial-centric diseases.

> **中文摘要：**
> 负载cGAS-STING通路抑制剂的DNA脂质纳米颗粒（DNA-LNPs）能够在体内安全有效地递送DNA。在此，我们报道了肝外DNA-LNP靶向的首批实例。与抗PECAM-1或VCAM-1抗体偶联的DNA-LNPs分别靶向肺部和大脑/脾脏的内皮系统。这些LNPs在其靶器官中驱动强健的转基因表达，其强度和持续时间均优于非靶向LNPs。PECAM靶向转基因表达的肺特异性在两周内逐渐增加，导致肺与肝的表达比例显著高于我们之前报道的PECAM靶向mRNA-LNPs。脱靶的肝脏DNA表达下降至检测不到的水平，但在肺部持久存在，而mRNA表达则因其短半衰期而统一减少。我们通过使用Fab片段取代全长抗体，进一步提高了这种表达特异性。单细胞分析揭示了器官特异性改善背后的关键机制：靶器官的表达由长寿命的内皮细胞主导，而脱靶的肝脏递送和表达则发生在半衰期较短的非内皮细胞中。总的来说，这些研究证明了靶向DNA-LNPs实现了高水平的器官和细胞类型特异性转基因表达，从而为数十种以内皮细胞为核心的疾病提供了治疗平台。

### 第二部分 AI 大师评价

该研究成功实现了DNA脂质纳米颗粒（DNA-LNP）的首次肝外靶向，通过抗体（如PECAM-1、VCAM-1）或Fab片段修饰实现了对肺、脑及脾脏内皮细胞的精准递送。相比于传统的mRNA递送系统，该平台利用长寿命内皮细胞的生物学特性，显著延长了转基因在靶器官的表达时长，并有效解决了肝脏脱靶表达的持久性问题。研究通过单细胞测序深度揭示了细胞周转动力学对表达特异性的调控机制，为内皮相关疾病的精准基因治疗提供了极具临床转化潜力的工程化技术支撑。

---

## 11. 基础模型赋能的多模态深度学习在缺失模态下的结直肠癌预后预测：一项多中心回顾性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556415)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41556415
**DOI：** 10.1002/advs.202510931

### 第一部分 原文与翻译

**英文原标题：** Foundation Model-Enabled Multimodal Deep Learning for Prognostic Prediction in Colorectal Cancer with Incomplete Modalities: A Multi-Institutional Retrospective Study.

> **英文摘要：**
> Accurate prognostic prediction for colorectal cancer is essential for optimizing personalized treatment strategies and improving patient outcomes. Current unimodal approaches encounter significant limitations in effectively leveraging multimodal data and confront challenges with the issue of missing modalities. A novel multimodal deep learning framework named FLARE, which integrates pathological images, radiological imaging, and clinical text reports, is introduced to provide accurate risk assessments for colorectal cancer survival and progression. FLARE employs foundation models to achieve efficient feature extraction, utilizes an attention-based multi-branch framework to enhance synergy and distinctiveness across modalities, and incorporates a diversity-promoting loss function. To address the issue of incomplete data, FLARE integrates modality and missing-aware prompts, pseudo embeddings, and a modality-level augmentation strategy, thereby effectively mitigating potential performance degradation. The performance of FLARE is retrospectively assessed using a dataset of 1679 colorectal cancer patients from four independent clinical centers. Its superior prognostic capability is demonstrated through Kaplan-Meier analysis and the concordance index. FLARE effectively stratified patients into high- and low-risk groups. It achieved the highest concordance index across all validation cohorts, significantly outperforming traditional clinical models and existing multimodal methods, thereby highlighting its robust generalizability. Interpretability was enhanced by the comprehensive analyses of clinical factors, immune infiltration patterns, and gene pathways, as well as visualizations of feature importance across multiple modalities. In summary, FLARE establishes a comprehensive and robust framework for multimodal deep learning in medical prognostics, providing an advanced Artificial intelligence, Multimodal Deep Learning, Prognosis prediction, colorectal cancer, foundation modeltool for precision cancer prognosis and intelligent diagnosis.

> **中文摘要：**
> 结直肠癌的准确预后预测对于优化个性化治疗策略和改善患者预后至关重要。当前的单模态方法在有效利用多模态数据方面存在显著局限，并面临缺失模态问题的挑战。本研究引入了一种名为 FLARE 的新型多模态深度学习框架，该框架整合了病理图像、放射学影像和临床文本报告，旨在为结直肠癌的生存和进展提供准确的风险评估。FLARE 采用基础模型实现高效的特征提取，利用基于注意力的多分支框架来增强模态间的协同作用和独特性，并纳入了促进多样性的损失函数。为了解决数据不完整的问题，FLARE 整合了模态和缺失感知的提示、伪嵌入以及模态级增强策略，从而有效地缓解了潜在的性能下降。本研究利用来自四个独立临床中心的 1679 名结直肠癌患者的数据集，对 FLARE 的性能进行了回顾性评估。通过 Kaplan-Meier 分析和一致性指数（C-index）证明了其卓越的预后能力。FLARE 有效地将患者分为高风险组和低风险组。它在所有验证队列中均取得了最高的一致性指数，显著优于传统临床模型和现有的多模态方法，从而凸显了其强大的泛化能力。通过对临床因素、免疫浸润模式和基因通路的全面分析，以及跨多个模态的特征重要性可视化，增强了模型的可解释性。总之，FLARE 为医学预后中的多模态深度学习建立了一个全面且稳健的框架，为癌症精准预后和智能诊断提供了一种先进的工具。

### 第二部分 AI 大师评价

该研究开发了名为 FLARE 的多模态深度学习框架，旨在解决结直肠癌预后预测中多模态数据融合及模态缺失的关键瓶颈。通过集成基础模型和针对性的提示学习策略，FLARE 在 1679 例多中心数据集上展现了优于传统模型的一致性指数和稳健的泛化能力。其创新性在于利用伪嵌入和增强策略有效应对了临床中常见的数据缺失问题，并结合生物学通路分析显著提升了黑盒模型的可解释性，为临床决策提供了高价值的智能预测方案。

---

## 12. 仿生铱基光热纳米酶触发铁死亡与焦亡并激活cGAS-STING通路用于增强肿瘤免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556405)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41556405
**DOI：** 10.1002/advs.202519186

### 第一部分 原文与翻译

**英文原标题：** Biomimetic Iridium-Based Photothermal Nanozyme to Trigger Ferroptosis and Pyroptosis and Activate the cGAS-STING Pathway for Improved Tumor Immunotherapy.

> **英文摘要：**
> Although nanozymes are potential tumor therapeutics due to their ability to disrupt intracellular redox homeostasis, developing nanozymes with higher therapeutic efficacy and clarifying their antitumor mechanism are challenging. Here, an iridium (Ir)-based nanozyme (IIN) was constructed through coordination-driven co-assembly using photosensitizer indocyanine green (ICG), Ir, and indoleamine 2,3-dioxygenase (IDO) inhibitor NLG8189. Then, the IIN was mimicked by tumor cell lysate (TCL)-simulated dendritic cell (DC) membrane to form IIN@M. Based on superior enzyme-like activity and photothermal performance, IIN@M disrupted the intracellular redox homeostasis by generating reactive oxygen species (ROS) and depleting glutathione (GSH). GSH depletion induced ferroptosis, and ROS burst under photothermal irradiation triggered pyroptosis, thus synergistically enhancing immunogenic cell death (ICD). The generated ROS could promote mitochondrial DNA (mtDNA) oxidative damage and release, finally activating the immune response by the cyclic GMP-AMP synthase-simulator of interferon gene (cGAS-STING) pathway. In vivo experiments also suggested that IIN@M could efficiently ablate the primary tumor, especially under photothermal irradiation. Furthermore, it could suppress distant tumor progression by triggering the immune response, especially under photothermal irradiation, which was accompanied by increased DC maturation, M1 macrophage polarization, and T cell infiltration in tumor tissue. This study proposed a promising strategy for effective Ir-based nanozyme in tumor immunotherapy.

> **中文摘要：**
> 尽管纳米酶因其破坏细胞内氧化还原稳态的能力而具有作为潜在肿瘤治疗药物的潜力，但开发具有更高治疗效力的纳米酶并阐明其抗肿瘤机制仍具有挑战性。在此，通过光敏剂吲哚菁绿（ICG）、铱（Ir）和吲哚胺 2,3-双加氧酶（IDO）抑制剂 NLG8189 的配位驱动共组装，构建了一种铱（Ir）基纳米酶（IIN）。随后，利用肿瘤细胞裂解物（TCL）模拟的树突状细胞（DC）膜对 IIN 进行仿生化封装，形成 IIN@M。基于优异的类酶活性和光热性能，IIN@M 通过产生活性氧（ROS）和消耗谷胱甘肽（GSH）破坏了细胞内的氧化还原稳态。GSH 的耗竭诱导了铁死亡，而光热照射下的 ROS 爆发触发了细胞焦亡，从而协同增强了免疫原性细胞死亡（ICD）。产生的 ROS 可促进线粒体 DNA（mtDNA）的氧化损伤和释放，最终通过环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子（cGAS-STING）通路激活免疫反应。体内实验还表明，IIN@M 能有效消融原发肿瘤，尤其是在光热照射下。此外，它还能通过触发免疫反应抑制远处肿瘤的进展，特别是在光热照射下，这伴随着肿瘤组织中 DC 成熟、M1 型巨噬细胞极化和 T 细胞浸润的增加。本研究为开发用于有效肿瘤免疫治疗的铱基纳米酶提供了一种极具前景的策略。

### 第二部分 AI 大师评价

该研究成功设计并构建了一种集光热治疗、化学动力学治疗与免疫治疗于一体的仿生铱基纳米酶（IIN@M）。其核心创新在于通过诱导铁死亡与焦亡的协同作用增强免疫原性细胞死亡（ICD），并首次深入探讨了通过ROS介导的mtDNA损伤激活cGAS-STING通路以增强全身性抗肿瘤免疫的机制。体内实验结果显著，不仅能有效清除原发灶，还能抑制远端未照射肿瘤，为开发多模态协同治疗纳米平台提供了重要的实验依据和理论支撑。

---

## 13. DEL-1 是一种抑制衰老相关骨丢失的内源性衰老细胞清除蛋白

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556369)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41556369
**DOI：** 10.1002/advs.202509263

### 第一部分 原文与翻译

**英文原标题：** DEL-1 is an Endogenous Senolytic Protein that Inhibits Senescence-Associated Bone Loss.

> **英文摘要：**
> Accumulation of senescent cells in the bone microenvironment, including bone marrow mesenchymal stromal cells (BM-MSCs), contributes to aging-related bone degeneration. Developmental endothelial locus-1 (DEL-1), the expression of which declines with old age is herein described as an endogenous secreted senolytic protein. DEL-1 promotes apoptosis of senescent BM-MSCs via a β3 integrin/CD73/adenosine/p38 mitogen-activated protein kinase (p38 MAPK)/B-cell lymphoma-2 (BCL-2) pathway, thereby leading to their clearance by macrophages. DEL-1-deficiency displays increased abundance of β3 integrin-rich CD73 senescent BM-MSCs and higher chemotherapy-induced or aging-related senescence-associated bone loss. Conversely, mice with endothelial-specific overexpression of DEL-1 (EC-Del1) have decreased numbers of senescent BM-MSCs and diminish senescence-associated bone loss. CD73-deficiency reverses the reduction in senescent BM-MSC numbers in EC-Del1 mice. Administration of DEL-1 (or a DEL-1-inducing macrolide) causes a reduction in senescence markers and reverses aging-related periodontitis. Therefore, DEL-1 may be harnessed as an endogenous senolytic to prevent senescent cell buildup and senescence-associated bone loss.

> **中文摘要：**
> 骨微环境中衰老细胞（包括骨髓间充质基质细胞，BM-MSCs）的积累会导致与年龄相关的骨变性。发育内皮位点-1（DEL-1）的表达随年龄增长而下降，本文将其描述为一种内源性分泌的衰老细胞清除（senolytic）蛋白。DEL-1 通过 β3 整合素/CD73/腺苷/p38 丝裂原活化蛋白激酶 (p38 MAPK)/B 细胞淋巴瘤-2 (BCL-2) 通路促进衰老 BM-MSCs 的凋亡，从而导致其被巨噬细胞清除。DEL-1 缺乏会导致富含 β3 整合素的 CD73 衰老 BM-MSCs 丰度增加，并加剧化疗诱导或衰老相关的骨丢失。相反，内皮特异性过表达 DEL-1 (EC-Del1) 的小鼠衰老 BM-MSCs 数量减少，并减轻了衰老相关的骨丢失。CD73 缺失逆转了 EC-Del1 小鼠中衰老 BM-MSC 数量的减少。给予 DEL-1（或一种诱导 DEL-1 的大环内酯类药物）可减少衰老标志物并逆转衰老相关的牙周炎。因此，DEL-1 可作为一种内源性衰老细胞清除剂，用于预防衰老细胞积累和衰老相关的骨丢失。

### 第二部分 AI 大师评价

本研究鉴定出 DEL-1 是一种新型内源性衰老细胞清除蛋白，揭示了其通过 β3 整合素/CD73 轴精准诱导衰老骨髓间充质基质细胞凋亡的分子机制。通过基因缺失与内皮特异性过表达模型，研究有力证实了 DEL-1 在缓解化疗及自然衰老所致骨丢失中的核心作用。该发现不仅拓展了内源性抗衰老因子的认知边界，还为通过药物诱导 DEL-1 开发针对骨退行性疾病及牙周炎的创新疗法提供了重要靶点。

---

## 14. PRDM1+ 恶性细胞介导食管鳞状细胞癌对新辅助放化疗联合免疫治疗的免疫抑制格局及耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556358)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41556358
**DOI：** 10.1002/advs.202515207

### 第一部分 原文与翻译

**英文原标题：** PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma.

> **英文摘要：**
> The mechanisms underlying resistance to neoadjuvant immunotherapy and chemoradiotherapy (nICRT) in locally advanced esophageal squamous cell carcinoma (ESCC) remain poorly understood. Through a single-arm phase II trial (n = 22) with 44.4-month median follow-up, we observed a significant survival disparity: patients achieving major pathologic response (MPR) exhibited superior 3-year event-free survival (EFS) and overall survival (OS), with no recurrence in MPR patients versus 71.4% recurrence in non-major pathological response (NMPR) patients (HR = 17.69, 95% CI 2.25-139.20, p = 0.0063). Integrating single-cell RNA/TCR sequencing and functional validation, we identified a PRDM1+ malignant cell subcluster enriched in NMPR patients and associated with treatment resistance. These cells exhibit strong lipid peroxidation characteristics, a state linked to the transcriptional activation of CTSB and MFSD12 mediated by PRDM1. This state renders the PRDM1+ malignant cell cluster more susceptible to ferroptosis induction. PRDM1+ cells further recruited immunosuppressive regulatory T cells (Tregs) through IL1A-IL1R2 interactions and activated lipid-metabolizing TREM2+ macrophages via CD47-SIRPA signaling, fostering an immune-evasive microenvironment. Conversely, MPR patients displayed expanded cytotoxic T-effector clones with enhanced tumor-killing capacity. Our findings identify PRDM1 as a key factor associated with nICRT resistance and suggest that targeting ferroptosis pathways or disrupting PRDM1+ cell-mediated immune suppression may represent a viable strategy in ESCC. Clinical trial registration number: NCT03940001.

> **中文摘要：**
> 局部晚期食管鳞状细胞癌（ESCC）对新辅助免疫治疗联合放化疗（nICRT）耐药的机制目前尚不清楚。通过一项中位随访时间为44.4个月的单臂II期临床试验（n = 22），我们观察到显著的生存差异：获得主要病理缓解（MPR）的患者表现出更优的3年无事件生存期（EFS）和总生存期（OS），其中MPR患者无复发，而未获得主要病理缓解（NMPR）的患者复发率为71.4%（HR = 17.69, 95% CI 2.25-139.20, p = 0.0063）。结合单细胞RNA/TCR测序和功能验证，我们鉴定出一群富集于NMPR患者并与治疗耐药相关的PRDM1+恶性细胞亚群。这些细胞表现出强烈的脂质过氧化特征，这种状态与PRDM1介导的CTSB和MFSD12的转录激活有关。这种状态使得PRDM1+恶性细胞簇对铁死亡诱导更加敏感。PRDM1+细胞通过IL1A-IL1R2相互作用进一步招募免疫抑制性调节性T细胞（Tregs），并通过CD47-SIRPA信号传导激活代谢脂质的TREM2+巨噬细胞，从而营造出免疫逃逸的微环境。相反，MPR患者显示出具有更强肿瘤杀伤能力的细胞毒性T效应细胞克隆发生扩增。我们的研究结果确定PRDM1是与nICRT耐药相关的关键因素，并表明针对铁死亡途径或阻断PRDM1+细胞介导的免疫抑制可能是ESCC的一种可行策略。临床试验注册号：NCT03940001。

### 第二部分 AI 大师评价

该研究通过一项随访时间超过44个月的II期临床试验，结合单细胞多组学技术，系统揭示了食管鳞癌对新辅助免疫放化疗耐药的深度机制。研究核心在于鉴定出PRDM1+恶性细胞亚群，证明其不仅通过脂质过氧化增强铁死亡敏感性，更通过招募Tregs和激活脂质代谢相关巨噬细胞构建免疫抑制微环境。该发现为克服ESCC耐药提供了精准的分子靶点（PRDM1）及治疗方向（铁死亡与免疫调节联合），具有极高的临床转化潜力，但在样本量扩充方面仍有进一步研究空间。

---

## 15. S3RL：通过可分离表示学习增强空间单细胞转录组学

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556263)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41556263
**DOI：** 10.1002/advs.202516178

### 第一部分 原文与翻译

**英文原标题：** S3RL: Enhancing Spatial Single-Cell Transcriptomics With Separable Representation Learning.

> **英文摘要：**
> Spatial transcriptomics enables in situ mapping of gene expression, offering insights into tissue organization and cell-cell interactions. However, its utility is limited by data sparsity and technical noise for decoding complex tissue microenvironments. Here, we introduce S3RL, a separable representation learning framework designed to enhance the fidelity of raw spatial transcriptomic data. By effectively denoising sparse measurements and amplifying biologically relevant signals, S3RL enables the recovery of fine-grained spatial expression patterns and regulatory relationships that are otherwise lost. Applied across diverse human, mouse and plant tissues, S3RL not only achieved improved accuracy in spatial domain identification and multi-slice alignment (up to 170% ARI improvement), but also uncovered previously unrecognized ligand-receptor signaling and spatial gene expression gradients that are critical for understanding immune-tumor crosstalk and plant developmental trajectories. These results establish S3RL as a powerful tool for extracting latent biological programs from noisy spatial transcriptomic datasets, paving the way for deeper exploration of tissue biology and disease mechanisms.

> **中文摘要：**
> 空间转录组学能够实现基因表达的原位映射，为组织结构和细胞间相互作用提供见解。然而，由于数据稀疏性和技术噪声的影响，其在解码复杂组织微环境方面的应用受到限制。在此，我们介绍了 S3RL，这是一种旨在增强原始空间转录组数据保真度的可分离表示学习框架。通过有效去除稀疏测量中的噪声并放大生物学相关信号，S3RL 能够恢复原本会丢失的细粒度空间表达模式和调控关系。在多种人类、小鼠和植物组织的应用中，S3RL 不仅显著提高了空间域识别和多切片比对的准确性（调整兰德系数 ARI 提升高达 170%），还揭示了此前未被发现的配体-受体信号传导和空间基因表达梯度，这些对于理解免疫-肿瘤通讯和植物发育轨迹至关重要。这些结果证明 S3RL 是从高噪声空间转录组数据集中提取潜在生物学程序的强大工具，为深入探索组织生物学和疾病机制铺平了道路。

### 第二部分 AI 大师评价

S3RL 针对空间转录组数据中固有的稀疏性与噪声挑战，提出了一种创新的可分离表示学习框架。该算法通过精准的信号解耦与去噪处理，在空间域识别及多样本对齐精度（ARI）上实现了质的飞跃，显著优于现有主流方法。该研究不仅展现了算法在跨物种（人、鼠、植物）应用中的强大泛化性，更在揭示细微生物学梯度与细胞通讯机制方面体现了卓越的生物学洞察力。

---

## 16. 工程化 CAR-NKT 细胞外囊泡抑制肿瘤进展并增强抗肿瘤免疫

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556250)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41556250
**DOI：** 10.1002/advs.202521623

### 第一部分 原文与翻译

**英文原标题：** Engineered CAR-NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity.

> **英文摘要：**
> Chimeric antigen receptor-engineered natural killer T (CAR-NKT) cell therapy represents a promising and innovative strategy in cancer immunotherapy, but is limited by acute toxicity and adverse effects, restricting broader clinical application despite durable responses. In this study, a novel nanobody targeting TM4SF1 is developed, which replaced the conventional single-chain variable fragment (scFv) in the design of CAR-NKT cells. Moreover, CAR-extracellular vesicles (EVs) therapy as an optimized alternative to direct CAR-NKT cell administration is introduced. Compared with conventional CAR engineered cells, CAR-EVs demonstrated superior antitumor efficacy while significantly reducing toxicity. This findings revealed that CAR-EVs selectively targeted TM4SF1-expressing tumor cells in both in vitro and in vivo models. In hepatocellular carcinoma (HCC) mouse models, CAR-EVs induced immunogenic cell death (ICD) and effectively suppressed tumor growth and metastasis. The therapeutic efficacy of CAR-EVs is primarily attributed to their ability to remodel the immunosuppressive tumor microenvironment (TME), notably by enhancing CD8⁺ T cell activity and eliciting robust antitumor immune responses. Furthermore, CAR-EVs synergized with Immune Checkpoint Blockade (ICB) therapy, leading to durable antitumor immune memory. Collectively, these findings establish CAR-EVs therapy as a safe and effective strategy for targeted cancer immunotherapy, underscoring its potential for clinical application.

> **中文摘要：**
> 嵌合抗原受体改造的自然杀伤 T（CAR-NKT）细胞疗法代表了癌症免疫治疗中一种极具前景的创新策略，但受限于急性毒性和副作用，尽管具有持久的反应，却限制了更广泛的临床应用。在本研究中，开发了一种针对 TM4SF1 的新型纳米抗体，用于替代 CAR-NKT 细胞设计中传统的单链可变片段（scFv）。此外，引入了 CAR 细胞外囊泡（EVs）疗法作为直接施用 CAR-NKT 细胞的优化替代方案。与传统的 CAR 改造细胞相比，CAR-EVs 展示了卓越的抗肿瘤效力，同时显著降低了毒性。研究结果显示，CAR-EVs 在体外和体内模型中均能选择性地靶向表达 TM4SF1 的肿瘤细胞。在肝细胞癌（HCC）小鼠模型中，CAR-EVs 诱导了免疫原性细胞死亡（ICD），并有效抑制了肿瘤的生长和转移。CAR-EVs 的治疗效力主要归因于它们重塑免疫抑制性肿瘤微环境（TME）的能力，特别是通过增强 CD8⁺ T 细胞活性并诱发强大的抗肿瘤免疫反应。此外，CAR-EVs 与免疫检查点阻断（ICB）疗法具有协同作用，从而产生持久的抗肿瘤免疫记忆。总而言之，这些发现确立了 CAR-EVs 疗法作为一种安全且有效的靶向癌症免疫治疗策略，强调了其临床应用的潜力。

### 第二部分 AI 大师评价

该研究针对传统 CAR-NKT 细胞疗法的毒副作用挑战，创新性地开发了基于纳米抗体（TM4SF1）的 CAR 细胞外囊泡（CAR-EVs）无细胞治疗系统。实验表明，CAR-EVs 不仅在肝细胞癌模型中表现出优于传统细胞疗法的靶向性和安全性，还通过诱导 ICD 和重塑肿瘤微环境显著提升了 CD8+ T 细胞介导的免疫反应。该研究不仅为减少免疫细胞疗法的毒性提供了新思路，还展示了其与免疫检查点抑制剂联用的巨大潜力，具有极高的临床转化价值。

---

## 17. 碱性磷酸酶激活的近红外二区（NIR-II）聚集诱导发光（AIEgens）纳米系统用于晚期骨肉瘤的手术及术后闭环治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41556090)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41556090
**DOI：** 10.1002/advs.202516035

### 第一部分 原文与翻译

**英文原标题：** Alkaline Phosphatase-Activated NIR-II AIEgens Nanosystem for Surgical and Postoperative Closed-Loop Therapy of Advanced Osteosarcoma.

> **英文摘要：**
> In advanced osteosarcoma, tumor invasion often prevents complete resection, and immunotherapy is limited by the tumor's immunosuppressive nature, making residual lesions a key source of recurrence. To address this, we developed an ALP-responsive theranostic nanoplatform (SGPF) integrating an AIEgens (STEA) and HSP90 inhibitor (Ganetespib) for imaging-guided resection and multimodal therapy. Selenium-doped STEA enables NIR-IIb imaging and enhanced phototherapy via narrowed HOMO-LUMO gaps and nonradiative decay optimization. At tumor sites, ALP-triggered nanomicelle cleavage releases STEA and Ganetespib while vaporizing perfluorohexane to relieve hypoxia. NIR irradiation induces pyroptosis via caspase-3/GSDME activation and immunogenic cell death, while Ganetespib suppresses glycolysis (HK2/PKM2 downregulation) to reverse lactate-driven immunosuppression. This dual-action strategy synergistically enhances T-cell infiltration and ablates residual/metastatic lesions, offering a transformative approach for unresectable Osteosarcoma.

> **中文摘要：**
> 在晚期骨肉瘤中，肿瘤侵袭通常阻碍彻底切除，且免疫疗法受限于肿瘤的免疫抑制特性，使得残留病灶成为复发的主要来源。为解决这一问题，我们开发了一种碱性磷酸酶（ALP）响应型诊疗纳米平台（SGPF），该平台集成了聚集诱导发光体（STEA）和HSP90抑制剂（Ganetespib），用于影像引导下的切除和多模态治疗。硒掺杂的STEA通过缩小最高占据分子轨道-最低未占据分子轨道（HOMO-LUMO）能隙和优化非辐射衰减，实现了近红外二区b波段（NIR-IIb）成像及增强的光疗效果。在肿瘤部位，ALP触发的纳米胶束裂解会释放STEA和Ganetespib，同时气化全氟己烷以缓解缺氧。近红外照射通过激活caspase-3/GSDME诱导细胞焦亡和免疫原性细胞死亡，而Ganetespib通过下调糖酵解途径（HK2/PKM2下调）来逆转乳酸驱动的免疫抑制。这种双重作用策略协同增强了T细胞浸润并消融了残留及转移病灶，为不可切除的骨肉瘤提供了一种变革性的治疗方法。

### 第二部分 AI 大师评价

该研究针对晚期骨肉瘤治疗中手术切除不彻底和免疫抑制导致的高复发率难题，开发了一种由碱性磷酸酶（ALP）激活的智能纳米诊疗平台。该系统巧妙结合了高性能NIR-IIb成像引导下的光疗与HSP90抑制剂介导的代谢重塑，通过诱导肿瘤细胞焦亡与逆转乳酸驱动的免疫抑制环境，实现了协同的抗肿瘤免疫应答。这种“影像引导+多模态协同”的闭环策略，不仅能精准清除术中残留病灶，还显著提升了对转移性病灶的杀伤效果，为临床治疗难治性骨肉瘤提供了极具潜力的创新方案。

---

## 18. ERBB3阻断通过抑制HIF1A-ABCB1信号通路，增强肝细胞癌在一线TKI耐药后对瑞戈非尼的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41555547)
**期刊：** Clinical and molecular hepatology
**PMID：** 41555547
**DOI：** 10.3350/cmh.2025.0972

### 第一部分 原文与翻译

**英文原标题：** ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling.

> **英文摘要：**
> BACKGROUND/AIMS: Regorafenib is recommended by guidelines and trials as a sequential second-line therapy following progression on first-line sorafenib or lenvatinib in hepatocellular carcinoma (HCC). However, efficacy is limited, highlighting the urgent need to screen suitable patients and develop sensitization strategies. METHODS: Acquired sorafenib- or lenvatinib-resistant (SR or LR) HCC cell lines and organoids were established. Genome-wide CRISPR library screen was performed in SR or LR cell strains to identify synthetic lethal targets of regorafenib. RNA-seq and FITC-regorafenib efflux assay were used to elucidate ERBB3-driven downstream signaling. Preclinical mouse models of cell line- and patient-derived xenografts and clinical cohorts of HCC patients were employed to validate the efficacy of ERBB3-guided patient stratification. RESULTS: Screening with CRISPR library, we showed that inhibition of ERBB3 was synthetic lethal with regorafenib in SR or LR cell strains and organoids. Mechanistically, sorafenib or lenvatinib resistance triggered feedback activation of ERBB3 signaling and mediated regorafenib efflux via ERBB3-HIF1A-ABCB1 cascade pathway, limiting sensitivity to regorafenib. Moreover, ERBB3-low tumors following sorafenib or lenvatinib resistance exhibited significant sensitivity to regorafenib, suggesting its potential as a predictive biomarker to screen optimal candidates for sequential therapy. Seribantumab, an ERBB3-targeting monoclonal antibody, inhibited ERBB3-HIF1A-ABCB1 cascade, and its combination with regorafenib exerted marked synergistic anti-tumor effects on ERBB3-high tumors resistant to sorafenib or lenvatinib both in vitro and in vivo. CONCLUSIONS: This study revealed that ERBB3 was a key resistance factor driving limited efficacy to sequential regorafenib, but also an effective therapeutic target whose inhibition enhanced regorafenib sensitivity after sorafenib or lenvatinib resistance.

> **中文摘要：**
> 背景/目的：指南和临床试验推荐瑞戈非尼作为肝细胞癌（HCC）在索拉非尼或仑伐替尼一线治疗进展后的序贯二线疗法。然而，由于其疗效有限，迫切需要筛选合适的患者并制定增敏策略。方法：建立获得性索拉非尼或仑伐替尼耐药（SR或LR）的HCC细胞系和类器官。在SR或LR细胞株中进行全基因组CRISPR文库筛选，以鉴定瑞戈非尼的合成致死靶点。通过RNA-seq和FITC-瑞戈非尼外排实验阐明ERBB3驱动的下游信号通路。采用细胞系和患者来源的异种移植（PDX）临床前小鼠模型以及HCC患者临床队列，验证基于ERBB3指导的患者分层策略的有效性。结果：通过CRISPR文库筛选，研究发现抑制ERBB3在SR或LR细胞株及类器官中与瑞戈非尼具有合成致死效应。机制上，索拉非尼或仑伐替尼耐药触发了ERBB3信号的反馈激活，并通过ERBB3-HIF1A-ABCB1级联通路介导瑞戈非尼外排，从而限制了对瑞戈非尼的敏感性。此外，索拉非尼或仑伐替尼耐药后的ERBB3低表达肿瘤对瑞戈非尼表现出显著敏感性，提示其具有作为预测性生物标志物以筛选序贯治疗最佳候选者的潜力。ERBB3靶向单克隆抗体Seribantumab可抑制ERBB3-HIF1A-ABCB1级联反应，其与瑞戈非尼联用在体内外均对索拉非尼或仑伐替尼耐药的ERBB3高表达肿瘤发挥了显著的协同抗肿瘤作用。结论：本研究揭示了ERBB3是导致序贯瑞戈非尼疗效有限的关键耐药因子，同时也是一个有效的治疗靶点，其抑制作用可增强一线TKI耐药后对瑞戈非尼的敏感性。

### 第二部分 AI 大师评价

本研究针对肝癌一线TKI耐药后二线瑞戈非尼疗效受限的临床难题，通过全基因组CRISPR筛选精准锁定了ERBB3这一关键耐药靶点。研究揭示了ERBB3-HIF1A-ABCB1信号轴介导药物外排的创新机制，并提出了基于ERBB3表达水平的患者分层及联合Seribantumab治疗的增敏策略。该研究不仅具有严密的生物学机制论证，还结合了类器官和PDX模型等转化医学手段，为晚期肝癌的精准治疗和克服多药耐药提供了坚实的实验依据。

---

## 19. COLEC12高表达肿瘤相关巨噬细胞通过旁分泌NRG1-HER2/HER3信号通路介导肝细胞癌的仑伐替尼耐药和癌症干性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41555545)
**期刊：** Clinical and molecular hepatology
**PMID：** 41555545
**DOI：** 10.3350/cmh.2025.1059

### 第一部分 原文与翻译

**英文原标题：** COLEC12high TAMs Orchestrate Lenvatinib Resistance and Cancer Stemness in HCC via Paracrine NRG1-HER2/HER3 Signaling.

> **英文摘要：**
> BACKGROUND/AIMS: Lenvatinib resistance remains a critical barrier in advanced hepatocellular carcinoma (HCC) therapy. However, the underlying mechanisms and strategies for reversing resistance remain incompletely understood. METHODS: Integrated transcriptomics of lenvatinib-resistant patient tumors and an acquired-resistance murine model identified a novel macrophage subpopulation. Functional validation employed CRISPR-SAM screening, conditioned medium (CM) assays, subcutaneous/orthotopic xenografts, patient-derived organoids (PDOs), and xenografts (PDXs). Mechanistic studies included ChIP-qPCR, co-immunoprecipitation, and pharmacologic targeting. Clinical relevance was assessed in a retrospective cohort. RESULTS: Resistant HCC exhibited significant enrichment of a COLEC12high TAM subset, which correlated with poor survival and treatment response. These TAMs secreted neuregulin-1 (NRG1), activating HER2/HER3-AKT signaling in tumor cells to drive cancer stemness and lenvatinib resistance. Mechanistically, in TAMs COLEC12 sequestered STAT1 in the cytoplasm, preventing its phosphorylation, and thereby derepressing STAT3-mediated neuregulin-1 (NRG1) transcription. Depletion of NRG1 reversed the stemness phenotypes and resensitized tumors to lenvatinib both in vitro and in vivo. Clinically, high NRG1 expression predicted an inferior lenvatinib response and shorter survival. Crucially, the bispecific anti-HER2/HER3 antibody zenocutuzumab restored lenvatinib efficacy in PDOs, PDXs, and murine models. CONCLUSIONS: Our work establishes the COLEC12high TAM / NRG1 axis as a master regulator of therapeutic resistance and identifies NRG1 as a predictive biomarker, providing a clinically actionable strategy to overcome lenvatinib resistance in HCC.

> **中文摘要：**
> 背景/目的：仑伐替尼耐药仍是晚期肝细胞癌（HCC）治疗中的关键障碍。然而，其潜在机制和逆转耐药的策略尚不完全明确。方法：通过对仑伐替尼耐药患者肿瘤和获得性耐药小鼠模型的整合转录组学分析，鉴定出一种新型巨噬细胞亚群。功能验证采用了CRISPR-SAM筛选、条件培养基（CM）实验、皮下/原位异种移植、患者来源的类器官（PDOs）和异种移植（PDXs）模型。机制研究包括染色质免疫共沉淀-定量PCR（ChIP-qPCR）、共免疫沉淀和药物靶向治疗。临床相关性在回顾性队列中进行了评估。结果：耐药性HCC表现出COLEC12高表达肿瘤相关巨噬细胞（TAM）子集的显著富集，这与较差的存活率和治疗反应相关。这些TAMs分泌神经调节蛋白-1（NRG1），激活肿瘤细胞中的HER2/HER3-AKT信号通路，从而驱动癌症干性和仑伐替尼耐药。从机制上讲，在TAMs中，COLEC12将STAT1螯合在细胞质中，阻止其磷酸化，从而解除对STAT3介导的NRG1转录的抑制。敲除NRG1可在体内外逆转干性表型并使肿瘤恢复对仑伐替尼的敏感性。临床上，NRG1的高表达预示着较差的仑伐替尼反应和较短的存活期。至关重要的是，双特异性抗HER2/HER3抗体zenocutuzumab在PDOs、PDXs和小鼠模型中恢复了仑伐替尼的疗效。结论：本研究确定了COLEC12高表达TAM/NRG1轴是治疗耐药的主要调节因子，并鉴定NRG1为预测性生物标志物，为克服HCC的仑伐替尼耐药提供了临床可行的策略。

### 第二部分 AI 大师评价

本研究通过整合多组学分析和多种临床前模型，揭示了肿瘤微环境中COLEC12阳性巨噬细胞介导仑伐替尼耐药的关键机制。研究创新性地阐明了COLEC12通过调控STAT1/STAT3轴促进NRG1旁分泌，进而激活肿瘤细胞HER2/HER3信号的级联反应。最具临床转化价值的是，研究证实了双特异性抗体Zenocutuzumab与仑伐替尼联合方案的有效性，为晚期肝癌的精准治疗提供了新的生物标志物和干预策略。

---

## 20. GPSeq 绘制真核基因组沿核外周-中心轴的径向组织图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41555070)
**期刊：** Nature protocols
**PMID：** 41555070
**DOI：** 10.1038/s41596-025-01278-x

### 第一部分 原文与翻译

**英文原标题：** GPSeq maps the radial organization of eukaryotic genomes along the nuclear periphery-center axis.

> **英文摘要：**
> Genomic loci positioning by sequencing (GPSeq) is a genome-wide method for mapping the radial organization of the genome in the nucleus of eukaryotic cells. GPSeq relies on in situ digestion of chromatin with a restriction enzyme that gradually diffuses inward from the nuclear periphery, followed by ligation of sequencing adapters to the digested restriction enzyme sites and library preparation for high-throughput sequencing. In parallel, ligation of labeled imaging adapters to the digested restriction enzyme recognition sites enables monitoring of the progression of radial digestion by fluorescence microscopy, providing an essential internal quality control before proceeding with sequencing. By comparing samples in which chromatin has been digested for increasing time intervals, a GPSeq score is calculated for every genomic bin into which the genome is arbitrarily divided, and genome-wide radial maps are generated with a resolution as high as 25 kb. These maps allow exploration of the radial distribution of (epi)genomic features, gene expression levels, mutational landscapes, and genomic profiles of DNA damage, when integrated with other omic data. Here, we present a detailed step-by-step protocol for performing GPSeq and preprocessing GPSeq data. The entire protocol requires ~2 weeks from the start of sample preparation to having ready-to-sequence libraries and intermediate levels of expertise in molecular biology, genomics and microscopy.

> **中文摘要：**
> 基因组位点测序定位（GPSeq）是一种在全基因组范围内绘制真核细胞核内基因组径向组织结构的方法。GPSeq 依赖于限制性内切酶对染色质进行的现场消化，该酶从核外周逐渐向内扩散，随后将测序接头连接到消化的限制性内切酶位点，并进行高通量测序的文库构建。与此同时，将标记的成像接头连接到消化的限制性内切酶识别位点，可以通过荧光显微镜监测径向消化的进展，在进行测序前提供必要的内部质量控制。通过比较在不断增加的时间间隔内消化染色质的样本，为基因组任意划分的每个基因组区间（bin）计算 GPSeq 评分，并生成分辨率高达 25 kb 的全基因组径向图谱。当与其他组学数据整合时，这些图谱可以用于探索（表观）基因组特征、基因表达水平、突变景观和 DNA 损伤基因组谱的径向分布。在此，我们提供了一个执行 GPSeq 和预处理 GPSeq 数据的详细步骤协议。整个方案从开始准备样品到获得可供测序的文库大约需要 2 周时间，并且需要具备分子生物学、基因组学和显微成像方面的中等水平专业知识。

### 第二部分 AI 大师评价

本文介绍了一种名为 GPSeq 的创新基因组学技术，旨在通过限制性内切酶从核外周向中心扩散消化的原理，在全基因组尺度上精确定位染色质的径向分布。该方法不仅实现了高达 25 kb 的高分辨率绘图，还创造性地结合了荧光显微成像作为测序前的质量控制手段，显著提高了实验的可靠性。GPSeq 为研究三维基因组空间组织与基因表达、DNA 损伤修复及表观遗传特征之间的空间相关性提供了强有力的工具。虽然该实验流程较为复杂且耗时较长，但其产生的径向分布得分对深入理解细胞核空间构象具有重要学术价值。

---

## 21. 工程化活体胶分泌治疗性蛋白质用于治疗炎症性肠病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41555021)
**期刊：** Nature biotechnology
**PMID：** 41555021
**DOI：** 10.1038/s41587-025-02970-9

### 第一部分 原文与翻译

**英文原标题：** Engineered living glues secrete therapeutic proteins for treatment of inflammatory bowel disease.

> **英文摘要：**
> Engineering bacteria to secrete gut therapeutics has been limited by their poor autonomous sensing of pathological cues and inability to sustain localized, long-term therapeutic activity. Here we engineer nonpathogenic Escherichia coli with a blood-inducible gene circuit that secretes the barnacle-derived adhesive protein CP43K and the therapeutic gut-barrier-healing factor TFF3 in response to gastrointestinal bleeding, an indicator of severe inflammatory bowel disease (IBD). Adhesive production enables sustained bacterial attachment to inflamed tissues for up to 10 days or 7 days following a single rectal or oral administration, respectively. This effect depends on bleeding-induced adhesion. Using two mouse models of IBD, the colitis model induced by dextran sulfate sodium and the interleukin-10-knockout mouse model, we demonstrate improved weight recovery, reversed colonic shortening and reduced intestinal bleeding. Additionally, the treatment decreases intestinal inflammation, promotes mucosal repair and restores gut barrier integrity, demonstrating comprehensive therapeutic efficacy.

> **中文摘要：**
> 改造细菌以分泌肠道治疗药物的努力一直受到其对病理信号的自主感知能力较差以及无法维持局部长期治疗活性的限制。在此，我们利用血液诱导基因回路改造了非致病性大肠杆菌，使其能够针对胃肠道出血（严重炎症性肠病 [IBD] 的一项指标）分泌藤壶来源的粘附蛋白 CP43K 和治疗性肠道屏障修复因子 TFF3。粘附蛋白的产生使细菌在单次直肠或口服给药后，分别能够在炎症组织上持续附着长达 10 天或 7 天。这种效应依赖于出血诱导的粘附。通过使用两种 IBD 小鼠模型（葡聚糖硫酸钠诱导的结肠炎模型和白细胞介素-10 敲除小鼠模型），我们证实了体重的改善恢复、结肠缩短的逆转以及肠道出血的减少。此外，该疗法降低了肠道炎症，促进了黏膜修复并恢复了肠道屏障的完整性，展示了全面的治疗功效。

### 第二部分 AI 大师评价

该研究创新性地开发了一种“活体胶”生物技术，通过赋予工程化大肠杆菌感知出血信号并原位分泌藤壶粘附蛋白的能力，突破了肠道工程菌定植时间短、精准度不足的临床痛点。实验证明，该系统能显著延长药物在炎症部位的留存，并在多种 IBD 小鼠模型中表现出优异的黏膜修复和抗炎效果。这一智能化给药平台为炎症性肠病的长效、精准干预提供了极具潜力的合成生物学解决方案。

---

## 22. 伊马替尼治疗的慢性髓系白血病在使用两种尼洛替尼巩固时长后的无治疗缓解：3期ENESTPath研究结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41555010)
**期刊：** Leukemia
**PMID：** 41555010
**DOI：** 10.1038/s41375-025-02847-5

### 第一部分 原文与翻译

**英文原标题：** Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.

> **英文摘要：**
> The phase 3 ENESTPath study investigated treatment-free remission (TFR) rates in patients with chronic Philadelphia chromosome-positive (Ph+) and/or BCR::ABL1 chronic myeloid leukemia who had not achieved deep molecular response (DMR) after >2 years of imatinib treatment and were switched to nilotinib 300 mg twice daily (BID). After 24 months of treatment, patients with a stable DMR were randomized to either enter the TFR phase (Arm 1) or continue nilotinib consolidation for an additional 12 months and then enter the TFR phase if in stable DMR (Arm 2). The primary endpoint was the proportion of patients who remained in TFR (≥MR [BCR::ABL1 ≤ 0.01%]) without molecular relapse at the end of 12 months. Of the 620 patients enrolled, 239 (38.5%) achieved stable MR and were randomized to Arm 1 (n = 120) or Arm 2 (n = 119). In the TFR phase, MR rates at 12 months (Arm 1: 31.9%, Arm 2: 37.5%; p = 0.383) and 24 months (Arm 1: 29.4%, Arm 2: 30.8%) revealed no differences in TFR success between 2 and 3 years of nilotinib. Irrespective of the consolidation duration, switching to nilotinib 300 mg BID provided the opportunity to achieve TFR if patients were unable to reach stable DMR with first-line imatinib.

> **中文摘要：**
> 3期ENESTPath研究调查了在接受伊马替尼治疗超过2年后未达到深层分子学反应（DMR），并转用尼洛替尼300 mg每日两次（BID）治疗的费城染色体阳性（Ph+）和/或BCR::ABL1慢性期慢性髓系白血病患者的无治疗缓解（TFR）率。治疗24个月后，达到稳定DMR的患者被随机分配进入TFR阶段（第1组）或继续接受另外12个月的尼洛替尼巩固治疗，若仍处于稳定DMR则随后进入TFR阶段（第2组）。主要终点是在12个月末保持TFR（≥MR4 [BCR::ABL1 ≤ 0.01%]）且无分子学复发的患者比例。在入组的620名患者中，239名（38.5%）达到了稳定的分子学反应并被随机分配到第1组（n = 120）或第2组（n = 119）。在TFR阶段，12个月（第1组：31.9%，第2组：37.5%；p = 0.383）和24个月（第1组：29.4%，第2组：30.8%）的分子学反应率显示，尼洛替尼巩固2年与3年之间的TFR成功率没有差异。无论巩固时间长短，对于无法通过一线伊马替尼达到稳定DMR的患者，转用尼洛替尼300 mg BID提供了实现TFR的机会。

### 第二部分 AI 大师评价

这项3期ENESTPath研究探讨了二代TKI尼洛替尼作为转换治疗在慢性髓系白血病（CML）中的应用，重点评价了不同巩固时长对无治疗缓解（TFR）的影响。研究结果显示，对于伊马替尼反应不佳的患者，转用尼洛替尼可使约38%的患者达到稳定深层分子学反应并尝试停药，且2年与3年的巩固时长在TFR成功率上并无显著差异。该研究为一线治疗未达深层缓解的患者提供了实现TFR的新策略，证明了转换治疗的临床价值，但也提示在此类特定人群中维持长期TFR仍具有挑战性。

---

## 23. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 24. 更正：肿瘤细胞来源的外泌体赋予间充质基质细胞促肿瘤能力。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554894)
**期刊：** Oncogene
**PMID：** 41554894
**DOI：** 10.1038/s41388-026-03678-z

### 第一部分 原文与翻译

**英文原标题：** Correction: Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献为针对原研究论文的勘误声明，原研究聚焦于肿瘤微环境中细胞外囊泡的信号传递机制。核心研究探讨了肿瘤源性外泌体如何重塑间充质基质细胞（MSCs）的表型，使其具备促进肿瘤进展的能力。此类勘误通常涉及实验数据、图表或作者贡献的修正，旨在确保学术论文的严谨性与准确性。尽管此处无摘要显示，但其原研究在揭示肿瘤微环境演化方面具有重要学术价值。

---

## 25. 棕榈酸触发的 B7H3 棕榈酰化促进免疫逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554753)
**期刊：** Nature communications
**PMID：** 41554753
**DOI：** 10.1038/s41467-026-68525-x

### 第一部分 原文与翻译

**英文原标题：** Palmitic acid-triggered B7H3 palmitoylation promotes immune escape.

> **英文摘要：**
> Colorectal cancer responds poorly to immune checkpoint blockade in most patients with microsatellite-stable (MSS) tumors, highlighting the need for alternative targets. B7H3 (CD276) is an immune checkpoint protein that is frequently overexpressed in tumors, but how it is maintained at high protein levels is unclear. Here we show that palmitic acid (PA) promotes B7H3 palmitoylation by the palmitoyltransferase ZDHHC24 at cysteine 496. This modification prevents B7H3 from binding to sequestosome 1 (SQSTM1, also called p62), limiting autophagic degradation and stabilizing B7H3, which suppresses CD8 T cell antitumor activity. Disrupting this pathway by mutating cysteine 496, or by deleting Zdhhc24 in a colitis-associated colorectal cancer (CAC) mouse model, enhances CD8 T cell responses. We also develop a cell-penetrant peptide that blocks the ZDHHC24-B7H3 interaction, boosts antitumor immunity, and synergizes with blockade of programmed cell death protein 1 (PD-1). These findings identify B7H3 palmitoylation as a targetable metabolic-immune node for colorectal cancer immunotherapy.

> **中文摘要：**
> 在大多数患有微卫星稳定（MSS）型肿瘤的患者中，结直肠癌对免疫检查点阻断疗法的反应较差，这凸显了寻找替代靶点的必要性。B7H3（CD276）是一种在肿瘤中频繁过表达的免疫检查点蛋白，但其如何维持在高水平蛋白状态尚不清楚。在此，我们表明棕榈酸（PA）通过棕榈酰转移酶 ZDHHC24 在半胱氨酸 496 位点促进 B7H3 的棕榈酰化修饰。这种修饰阻止了 B7H3 与螯合体 1（SQSTM1，也称为 p62）结合，从而限制了自噬降解并稳定了 B7H3，进而抑制了 CD8+ T 细胞的抗肿瘤活性。在炎症相关结直肠癌（CAC）小鼠模型中，通过突变半胱氨酸 496 或敲除 Zdhhc24 来阻断该通路，可增强 CD8+ T 细胞反应。我们还开发了一种细胞穿透肽，可阻断 ZDHHC24-B7H3 的相互作用，增强抗肿瘤免疫，并与程序性细胞死亡蛋白 1（PD-1）阻断剂具有协同作用。这些发现确定了 B7H3 棕榈酰化是结直肠癌免疫治疗中一个可靶向的代谢-免疫节点。

### 第二部分 AI 大师评价

本研究揭示了代谢物棕榈酸通过调控 ZDHHC24 介导的 B7H3 棕榈酰化修饰，在微卫星稳定（MSS）型结直肠癌免疫逃逸中的关键驱动作用。研究阐明了该修饰通过逃避 p62 介导的自噬降解来维持 B7H3 蛋白稳定性的分子机制，并利用小鼠模型验证了阻断该通路对提升 T 细胞免疫反应的有效性。其创新点在于开发了针对 ZDHHC24-B7H3 相互作用的细胞穿透肽，证明了代谢修饰位点作为免疫治疗新靶点的潜力，为克服结直肠癌免疫耐药提供了新策略。

---

## 26. G9a 介导的 H3K9me2 通过对细胞周期相关基因的表观遗传沉默来协调肠上皮再生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554751)
**期刊：** Nature communications
**PMID：** 41554751
**DOI：** 10.1038/s41467-026-68626-7

### 第一部分 原文与翻译

**英文原标题：** G9a-mediated H3K9me2 orchestrates intestinal epithelial regeneration through epigenetic silencing of cell cycle-related genes.

> **英文摘要：**
> Histone modifications play an important role in intestinal homeostasis and regeneration. Here, we identify histone H3 lysine 9 di-methylation (H3K9me2) as an epigenetic regulator of intestinal epithelial repair through mass spectrometry-based screening of histone modifications. We then find that H3K9me2 and its methyltransferase G9a levels are reduced during acute injury and progressively increase during regeneration in both mouse models and human clinical samples. Genetic ablation of G9a in intestinal epithelial cells or pharmacological inhibition of its enzymatic activity substantially impairs intestinal regeneration and reduces survival following irradiation. Mechanistically, integrative genomic analyses reveal that G9a-mediated H3K9me2 suppresses chromatin accessibility and transcriptional activity of cell cycle arrest genes, including Rb1cc1, Rb1, Cdkn1a, and Pten, thereby promoting intestinal stem cell proliferation. Furthermore, we elucidate that IL-4-STAT6 signaling controls G9a expression during regeneration, i.e., IL-4 upregulation leads to STAT6 phosphorylation and subsequent transcriptional activation of G9a. These findings establish the IL-4-STAT6-G9a-H3K9me2 regulatory axis as a critical epigenetic mechanism controlling intestinal regeneration with therapeutic potential for gastrointestinal disorders.

> **中文摘要：**
> 组蛋白修饰在肠道稳态和再生中发挥重要作用。在此，我们通过基于质谱的组蛋白修饰筛选，鉴定出组蛋白 H3 第 9 位赖氨酸二甲基化（H3K9me2）是肠上皮修复的表观遗传调节因子。随后我们发现，在小鼠模型和人类临床样本中，H3K9me2 及其甲基转移酶 G9a 的水平在急性损伤期间降低，并在再生过程中逐渐升高。肠上皮细胞中 G9a 的遗传敲除或其酶活性的药理学抑制会显著损害肠道再生，并降低辐照后的存活率。机制上，综合基因组分析显示，G9a 介导的 H3K9me2 抑制了细胞周期阻滞基因（包括 Rb1cc1、Rb1、Cdkn1a 和 Pten）的染色质可及性和转录活性，从而促进肠道干细胞增殖。此外，我们阐明了 IL-4-STAT6 信号通路在再生过程中控制 G9a 的表达，即 IL-4 上调导致 STAT6 磷酸化，随后激活 G9a 的转录。这些发现确立了 IL-4-STAT6-G9a-H3K9me2 调节轴是控制肠道再生的关键表观遗传机制，具有治疗胃肠道疾病的潜力。

### 第二部分 AI 大师评价

该研究通过质谱筛选和多组学分析，揭示了组蛋白甲基转移酶 G9a 及其修饰产物 H3K9me2 在肠上皮修复中的核心作用。研究严谨地构建了从免疫信号（IL-4-STAT6）到表观遗传修饰再到细胞周期基因沉默的调控全链条，并在小鼠模型和临床样本中得到了双重验证。这项工作不仅深化了对肠道稳态维持机制的理解，还为胃肠道损伤的临床治疗提供了极具前景的表观遗传靶点。

---

## 27. 双倍剂量伏美替尼一线治疗EGFR L858R突变的局部晚期或转移性非小细胞肺癌患者：一项前瞻性、多中心、II期研究（FIRM）。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554745)
**期刊：** Nature communications
**PMID：** 41554745
**DOI：** 10.1038/s41467-026-68554-6

### 第一部分 原文与翻译

**英文原标题：** Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).

> **英文摘要：**
> Progression-free survival (PFS) with first-line third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors remains suboptimal in EGFR L858R-mutated advanced non-small-cell lung cancer (NSCLC), highlighting a need for strategies to delay resistance. This single-arm, phase II study (FIRM; ChiCTR2200060897) evaluates first-line double-dose firmonertinib (160 mg/day) in adults with L858R-mutated locally advanced or metastatic NSCLC. With a median follow-up of 27.5 months in 33 patients, primary endpoint was a median PFS of 21.1 months. Secondary endpoints include an unreached median overall survival, an objective response rate of 75.8%, a disease control rate of 90.9%, and an 18-month PFS rate of 63.1%. Grade ≥3 treatment-emergent adverse events occur in 6.1% of patients. Baseline circulating tumor DNA (ctDNA) variant allele frequency predicts ctDNA clearance at cycle 3 day 1, which correlates with longer PFS. Double-dose firmonertinib shows promising efficacy and tolerability, supporting its preliminary potential as first-line treatment for EGFR L858R-mutated advanced NSCLC.

> **中文摘要：**
> 在携带EGFR L858R突变的晚期非小细胞肺癌（NSCLC）中，一线使用第三代表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）的无进展生存期（PFS）仍不理想，这凸显了探索延缓耐药策略的必要性。这项单臂、II期研究（FIRM；ChiCTR2200060897）评估了双倍剂量伏美替尼（160 mg/天）一线治疗携带L858R突变的局部晚期或转移性NSCLC成年患者的疗效。在对33名患者进行中位27.5个月的随访后，主要终点中位PFS达到了21.1个月。次要终点包括尚未达到的中位总生存期、75.8%的客观缓解率、90.9%的疾病控制率以及63.1%的18个月PFS率。6.1%的患者发生了3级及以上的治疗期间不良事件。基线循环肿瘤DNA（ctDNA）变异等位基因频率可预测第3周期第1天的ctDNA清除情况，且该清除与更长的PFS相关。双倍剂量伏美替尼显示出令人鼓舞的疗效和耐受性，支持其作为EGFR L858R突变晚期NSCLC一线治疗方案的初步潜力。

### 第二部分 AI 大师评价

本研究（FIRM）针对EGFR L858R突变这一难治性亚组，探索了通过提高伏美替尼剂量（160mg）来增强疗效的治疗策略。结果显示中位PFS高达21.1个月，显著优于传统三代TKI标准剂量在L858R人群中的表现，且≥3级不良事件发生率极低（6.1%），安全性表现优异。研究还通过动态ctDNA监测揭示了分子层面缓解与临床获益的相关性，为优化L858R突变患者的一线精准治疗提供了有力的高质量证据。

---

## 28. 破坏铁稳态使胰腺癌对不可逆电穿孔敏感

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554743)
**期刊：** Nature communications
**PMID：** 41554743
**DOI：** 10.1038/s41467-026-68585-z

### 第一部分 原文与翻译

**英文原标题：** Disruption of iron homeostasis sensitizes pancreatic cancer to irreversible electroporation.

> **英文摘要：**
> Irreversible electroporation (IRE) is an ablative treatment for pancreatic cancer. It utilizes high-intensity pulsed electric field (PEF) to eliminate cancer cells by irreversibly disrupting cell membranes. However, PEF intensity is distributed unevenly; and cancer cells may survive in regions where it falls below the threshold of complete ablation. We find that iron-base metal organic framework nanoparticles (MOF-Fe) sensitize pancreatic cancer cells to PEF by inducing iron overload and ferroptosis. But their efficacy is diminished by the upregulation of ferritin heavy chain 1 (FTH1), a cellular response to restore iron homeostasis. C20U4V, a proteolysis targeting chimera (PROTAC) derived from arachidonic acid, degrades FTH1 and potentiates MOF-Fe-induced ferroptosis. It is then encapsulated in reactive oxygen species (ROS)-responsive micelles. The resulting M-C20U4V, when combined with MOF-Fe, efficiently induces ferroptosis and boosts PEF ablation efficacy. Therefore, disruption of iron homeostasis represents a potential strategy to lower the risk of tumor recurrence after IRE.

> **中文摘要：**
> 不可逆电穿孔（IRE）是胰腺癌的一种消融治疗方法。它利用高强度脉冲电场（PEF）通过不可逆地破坏细胞膜来清除癌细胞。然而，PEF强度分布不均匀；在强度低于完全消融阈值的区域，癌细胞可能会存活。我们发现，铁基金属有机框架纳米颗粒（MOF-Fe）通过诱导铁过载和铁死亡，使胰腺癌细胞对PEF敏感。但由于铁蛋白重链1（FTH1）的上调，其疗效有所降低，这是恢复铁稳态的一种细胞反应。C20U4V是一种衍生自花生四烯酸的蛋白降解靶向嵌合体（PROTAC），可降解FTH1并增强MOF-Fe诱导的铁死亡。随后将其封装在活性氧（ROS）响应型胶束中。由此产生的M-C20U4V与MOF-Fe结合使用时，能有效诱导铁死亡并提高PEF的消融效率。因此，破坏铁稳态是降低IRE后肿瘤复发风险的一种潜在策略。

### 第二部分 AI 大师评价

该研究针对胰腺癌不可逆电穿孔（IRE）消融不彻底导致复发风险高的临床痛点，提出了一种创新的协同治疗策略。通过利用铁基纳米框架诱导铁死亡，并辅以新型PROTAC分子C20U4V定向降解FTH1蛋白，成功克服了癌细胞对铁过载的代偿性调节机制。该研究不仅开发了ROS响应型高效递送系统，还从代谢稳态调节的角度为增强物理消融疗效、降低术后复发风险提供了坚实的理论依据和技术路径。

---

## 29. 基因组语言模型缓解纳米孔直接RNA测序中的嵌合体伪影

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554734)
**期刊：** Nature communications
**PMID：** 41554734
**DOI：** 10.1038/s41467-026-68571-5

### 第一部分 原文与翻译

**英文原标题：** Genomic language model mitigates chimera artifacts in nanopore direct RNA sequencing.

> **英文摘要：**
> Chimera artifacts in nanopore direct RNA sequencing (dRNA-seq) introduce substantial inaccuracies, complicating downstream applications such as transcript annotation and gene fusion detection. Current basecalling models are unable to detect or mitigate these artifacts, limiting the reliability and utility of dRNA-seq for transcriptomics research. To address this challenge, we present DeepChopper, a genomic language model specifically designed to identify and remove adapter sequences from base-called dRNA-seq long reads with single-base precision. Operating independently of raw signal or alignment information, DeepChopper effectively eliminates adapter-bridged artifacts. Here, we show that DeepChopper enhances the accuracy of downstream analyses and unlocks the full potential of nanopore dRNA-seq, establishing it as a more robust tool for diverse transcriptomics applications.

> **中文摘要：**
> 纳米孔直接RNA测序（dRNA-seq）中的嵌合体伪影会导致严重的不准确性，使转录本注释和基因融合检测等下游应用变得复杂。目前的碱基识别模型无法检测或缓解这些伪影，限制了dRNA-seq在转录组学研究中的可靠性和实用性。为了应对这一挑战，我们提出了DeepChopper，这是一种基因组语言模型，专门设计用于以单碱基精度从碱基识别后的dRNA-seq长读段中识别并去除接头序列。DeepChopper的运行独立于原始信号或比对信息，能有效消除接头桥接产生的伪影。在此，我们展示了DeepChopper增强了下游分析的准确性，并释放了纳米孔dRNA-seq的全部潜力，使其成为多种转录组学应用的更稳健工具。

### 第二部分 AI 大师评价

该研究针对纳米孔直接RNA测序中普遍存在的嵌合体伪影难题，开发了基于基因组语言模型的创新工具DeepChopper。该模型不依赖原始信号或序列比对，仅凭序列信息即可实现单碱基精度的接头识别与切除，显著提升了测序数据的质量。这一方法有效解决了转录本注释及融合基因检测中的准确性瓶颈，为长读段转录组学研究提供了一个极具应用价值的高精度预处理方案。

---

## 30. Knowledge Connector：用于多组学精准肿瘤学的决策支持系统

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554728)
**期刊：** Nature communications
**PMID：** 41554728
**DOI：** 10.1038/s41467-026-68333-3

### 第一部分 原文与翻译

**英文原标题：** The Knowledge Connector decision support system for multiomics-based precision oncology.

> **英文摘要：**
> Precision cancer medicine aims to improve patient outcomes by providing individually tailored recommendations for clinical management based on the evaluation of biological disease profiles in multidisciplinary molecular tumor boards (MTBs). The quality of MTB decisions depends on the comprehensive, reliable, and reproducible interpretation of increasingly complex molecular data. We developed and implemented, as part of a multicenter precision oncology program, the Knowledge Connector (KC), a decision support system that integrates individual patients' molecular and clinical data with world knowledge to generate and document MTB recommendations. The KC supports data curation, database integration, and discussion based on multiomics data and provides an interface for creating a cross-institutional knowledge base. Furthermore, it extracts relevant biomarker-drug associations and increases the efficacy of data interpretation in a clinically relevant manner by reducing reliance on external sources and optimizing inter-curator concordance. Our results demonstrate that the KC is a versatile tool that supports medical decision-making in MTBs, thus enabling the scalability of precision cancer medicine.

> **中文摘要：**
> 精准癌症医学旨在通过多学科分子肿瘤专家委员会（MTBs）对生物学疾病特征的评估，提供个体化的临床管理建议，从而改善患者预后。MTB 决策的质量取决于对日益复杂的分子数据进行全面、可靠且可重复的解读。作为多中心精准肿瘤学项目的一部分，我们开发并实施了 Knowledge Connector (KC)，这是一种决策支持系统，可将个体患者的分子和临床数据与全球知识相结合，以生成并记录 MTB 建议。KC 支持基于多组学数据的数据整理、数据库整合和讨论，并提供了一个用于构建跨机构知识库的接口。此外，它还能提取相关的生物标志物-药物关联，并通过减少对外部资源的依赖以及优化策展人之间的一致性，以临床相关的方式提高数据解读的效率。我们的结果表明，KC 是一个多功能工具，可支持 MTB 的医学决策，从而实现精准癌症医学的可扩展性。

### 第二部分 AI 大师评价

该研究开发并实施了名为 Knowledge Connector (KC) 的决策支持系统，旨在解决分子肿瘤专家委员会（MTB）在解读复杂多组学数据时面临的效率与一致性瓶颈。系统通过整合患者个体分子谱与全球医疗知识库，实现了生物标志物-药物关联的自动化提取与跨机构知识共享，显著降低了对外部人工检索的依赖。其核心创新点在于优化了临床数据整理流程并提升了决策的可重复性，为精准肿瘤学在大规模临床环境下的可扩展应用提供了关键的技术框架。

---

## 31. 分级机制控制 DNA 损伤停滞的 RNA 聚合酶 II 的清除

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554717)
**期刊：** Nature communications
**PMID：** 41554717
**DOI：** 10.1038/s41467-026-68413-4

### 第一部分 原文与翻译

**英文原标题：** Hierarchical mechanisms control the clearance of DNA lesion-stalled RNA polymerase II.

> **英文摘要：**
> Stalling of elongating RNA polymerase II (RNAPII) at DNA lesions blocks transcription and triggers transcription-coupled repair (TCR). However, the mechanisms determining the fate of stalled RNAPII remain incompletely understood. Here, we develop a time-resolved assay to track RNAPII clearance and degradation at UV-induced lesions. We show that RNAPII ubiquitylation by CSB and the CRL4 ubiquitin ligase is essential, as loss of these proteins causes persistent RNAPII accumulation at damage sites. Downstream of CSB/CRL4-mediated ubiquitylation, two distinct pathways mediate RNAPII removal. The primary rapid route relies on TFIIH, with its XPD helicase activity driving RNAPII dissociation after proper recruitment and positioning by ELOF1, UVSSA, and STK19. A secondary slow pathway is mediated by the ubiquitin-dependent segregase VCP, which compensates for impaired TFIIH function. While VCP contributes only minimally in TCR-proficient cells, inhibition of VCP in TFIIH-deficient contexts completely abrogates RNAPII clearance. Together, these findings establish a hierarchical program in which CSB/CRL4-mediated ubiquitylation initiates RNAPII processing, TFIIH/XPD helicase activity provides the main clearance mechanism, and VCP-dependent extraction acts as a backup when TFIIH fails. This mechanistic framework explains how cells resolve DNA lesion-stalled RNAPII during normal and compromised TCR.

> **中文摘要：**
> 延伸中的 RNA 聚合酶 II (RNAPII) 在 DNA 损伤处的停滞会阻碍转录并触发转录偶联修复 (TCR)。然而，决定停滞的 RNAPII 命运的机制仍不完全清楚。在此，我们开发了一种时间分辨分析法，用于追踪 UV 诱导损伤处 RNAPII 的清除和降解。我们发现，CSB 和 CRL4 泛素连接酶介导的 RNAPII 泛素化至关重要，因为这些蛋白的缺失会导致 RNAPII 在损伤位点持续积累。在 CSB/CRL4 介导的泛素化下游，两条不同的路径介导 RNAPII 的移除。主要的快速路径依赖于 TFIIH，其 XPD 解旋酶活性在经 ELOF1、UVSSA 和 STK19 正确招募和定位后驱动 RNAPII 解离。次要的慢速路径由泛素依赖性分离酶 VCP 介导，它补偿了受损的 TFIIH 功能。虽然 VCP 在 TCR 功能正常的细胞中贡献极小，但在 TFIIH 缺陷的情况下抑制 VCP 会完全取消 RNAPII 的清除。总之，这些发现建立了一个分级程序，其中 CSB/CRL4 介导的泛素化启动 RNAPII 处理，TFIIH/XPD 解旋酶活性提供主要的清除机制，而 VCP 依赖的提取在 TFIIH 失效时作为备份。这一机制框架解释了细胞在正常和受损的 TCR 过程中如何处理 DNA 损伤停滞的 RNAPII。

### 第二部分 AI 大师评价

该研究利用创新的时间分辨分析法，深入揭示了真核细胞清除 DNA 损伤位点停滞 RNAPII 的分级调控机制。研究确立了 CSB/CRL4 泛素化作为启动信号，并首次明确了以 TFIIH/XPD 介导的主动解离为主线、VCP 介导的备份提取为补充的协作关系。这一发现不仅完善了转录偶联修复（TCR）的基础理论框架，也为理解 TCR 功能受损相关的疾病机理提供了关键的分子解析。

---

## 32. 作者更正：系统性硬化症的全基因组关联分析（GWAS）确定了包括 Fcγ 受体区域在内的六个新易感位点。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554714)
**期刊：** Nature communications
**PMID：** 41554714
**DOI：** 10.1038/s41467-026-68405-4

### 第一部分 原文与翻译

**英文原标题：** Author Correction: GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

该文献是针对一项关于系统性硬化症（SSc）大规模遗传学研究的作者更正通报。原研究通过全基因组关联分析（GWAS）成功识别出六个全新的易感位点，特别是 Fcγ 受体区域的发现，为揭示该疾病的免疫遗传机制提供了关键证据。此类更正旨在修正原论文中的细节偏差或补充信息，体现了科学研究的严谨性。尽管本文档本身不含摘要，但其指向的原始研究在自身免疫性疾病的精准医疗和发病机制研究领域具有重要的学术价值。

---

## 33. 守护者泛素E3连接酶通过靶向癌症相关APOBEC3脱氨酶降解以促进人类基因组完整性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554709)
**期刊：** Nature communications
**PMID：** 41554709
**DOI：** 10.1038/s41467-026-68420-5

### 第一部分 原文与翻译

**英文原标题：** Guardian ubiquitin E3 ligases target cancer-associated APOBEC3 deaminases for degradation to promote human genome integrity.

> **英文摘要：**
> APOBEC family members play crucial roles in antiviral restriction. However, certain APOBEC3 (A3) proteins drive harmful hypermutation in humans, contributing to cancer. The cancer-associated A3 proteins are capable of transiting from the cytosol to the nucleus, where they can cause genome mutations. Here, we uncover a specific set of cellular pathways that protect genomic DNA from the major cancer-associated A3 proteins. Through genetic and proteomic screening, we identify UBR4, UBR5, and HUWE1 as key ubiquitin E3 ligases marking cancer-associated A3B and A3H-I for degradation, thereby limiting A3-driven hypermutation. Mechanistically, UBR5 and HUWE1 recognize A3s in the absence of their RNA binding partner, thus promoting proteasomal degradation of APOBEC3 protein that is not engaged in its antiviral cellular function. Depletion or mutation of the E3 ligases in cells and human cancer samples increases A3-driven genome mutagenesis. Our findings reveal that UBR4, UBR5, and HUWE1 are crucial factors in a ubiquitination cascade that maintains human genome stability.

> **中文摘要：**
> APOBEC家族成员在抗病毒限制中发挥着至关重要的作用。然而，某些APOBEC3 (A3) 蛋白会在人体内驱动有害的高突变，从而诱发癌症。这些癌症相关的A3蛋白能够从细胞质转运至细胞核，并在核内引起基因组突变。在本研究中，我们揭示了一组保护基因组DNA免受主要癌症相关A3蛋白侵害的特定细胞通路。通过遗传学和蛋白质组学筛选，我们鉴定出UBR4、UBR5和HUWE1是关键的泛素E3连接酶，它们能够标记癌症相关的A3B和A3H-I以进行降解，从而限制A3驱动的高突变。从机制上讲，UBR5和HUWE1在缺乏RNA结合伴侣的情况下识别A3，从而促进那些未参与抗病毒细胞功能的APOBEC3蛋白进行蛋白酶体降解。在细胞和人类癌症样本中，这些E3连接酶的缺失或突变会增加A3驱动的基因组诱变。我们的发现表明，UBR4、UBR5和HUWE1是维持人类基因组稳定性泛素化级联反应中的关键因子。

### 第二部分 AI 大师评价

本研究通过整合遗传学和蛋白质组学筛选技术，成功揭示了细胞防止APOBEC3蛋白引发基因组损伤的内在防御机制。研究的核心创新点在于发现了UBR4、UBR5和HUWE1三款E3连接酶通过识别非功能状态（未结合RNA）的A3蛋白来介导其降解，从而精准区分了A3的抗病毒功能与致癌风险。这一发现不仅深化了对泛素化调控基因组稳定性逻辑的理解，也为解释癌症中突变负荷增加的分子根源提供了重要证据，具有极高的学术价值和潜在的临床指导意义。

---

## 34. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 35. 更正：循环肿瘤 DNA 优化局限期小细胞肺癌患者的巩固免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554704)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41554704
**DOI：** 10.1038/s41392-025-02526-y

### 第一部分 原文与翻译

**英文原标题：** Correction: Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是针对一项关于循环肿瘤DNA（ctDNA）在局限期小细胞肺癌（LS-SCLC）巩固免疫治疗中应用研究的勘误。原研究的核心价值在于揭示了ctDNA作为生物标志物在评估微小残留病灶（MRD）及指导精准免疫治疗方面的潜力。此类勘误声明通常用于修正原始论文中的数据、图表或作者信息等技术细节，旨在维护学术发表的严谨性和数据的准确性，并不影响原研究关于ctDNA优化临床决策的核心科学结论。

---

## 36. 整合表观遗传学和转录组学鉴定人类血液中的衰老基因

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554691)
**期刊：** Nature communications
**PMID：** 41554691
**DOI：** 10.1038/s41467-025-67369-1

### 第一部分 原文与翻译

**英文原标题：** Integrative epigenetics and transcriptomics identify aging genes in human blood.

> **英文摘要：**
> Recent epigenome-wide studies have identified a large number of genomic regions that consistently exhibit changes in their methylation status with aging across diverse populations, but the functional consequences of these changes are largely unknown. On the other hand, transcriptomic changes are more easily interpreted than epigenetic alterations, but previously identified age-related gene expression changes have shown limited replicability across populations. Here, we develop an approach that leverages high-resolution multi-omic data for an integrative analysis of epigenetic and transcriptomic age-related changes and identify genomic regions associated with both epigenetic and transcriptomic age-dependent changes in blood. Our results show that these multi-omic aging genes in blood are enriched for adaptive immune functions, replicate more robustly across diverse populations and are more strongly associated with aging-related outcomes compared to the genes identified using epigenetic or transcriptomic data alone. These multi-omic aging genes may serve as targets for epigenetic editing to facilitate cellular rejuvenation.

> **中文摘要：**
> 最近的全表观基因组研究已在不同人群中鉴定出大量基因组区域，这些区域的甲基化状态随衰老而表现出一致的变化，但这些变化的功能后果在很大程度上仍是未知的。另一方面，转录组变化比表观遗传改变更容易解释，但先前鉴定的与年龄相关的基因表达变化在不同人群中的可复制性有限。在这里，我们开发了一种利用高分辨率多组学数据的方法，对表观遗传和转录组的年龄相关变化进行整合分析，并鉴定了血液中与表观遗传和转录组年龄依赖性变化相关的基因组区域。我们的结果表明，血液中的这些多组学衰老基因富集于适应性免疫功能，与仅使用表观遗传或转录组数据鉴定的基因相比，它们在不同人群中复制得更稳健，且与衰老相关结果的关联更强。这些多组学衰老基因可作为表观遗传编辑的目标，以促进细胞年轻化。

### 第二部分 AI 大师评价

该研究通过开发一种整合高分辨率表观遗传与转录组数据的多组学分析框架，成功克服了单组学数据在衰老研究中功能解释性差或跨人群可复制性低的瓶颈。研究在血液中鉴定出的多组学衰老基因不仅在适应性免疫功能中高度富集，且在多个人群队列中表现出极佳的稳健性，并与衰老临床结局显著相关。这一成果为理解人类生物学年龄的分子机制提供了新视角，并为通过表观遗传编辑精准干预衰老过程提供了潜在的分子靶点。

---

## 37. 饱和位点功能筛选识别出与乳腺癌风险增加相关的 PALB2 错义变异

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554690)
**期刊：** Nature communications
**PMID：** 41554690
**DOI：** 10.1038/s41467-025-67252-z

### 第一部分 原文与翻译

**英文原标题：** Site-saturation functional screens identify PALB2 missense variants associated with increased breast cancer risk.

> **英文摘要：**
> Loss-of-function variants in PALB2 give rise to defects in DNA damage repair by homologous recombination (HR), increasing the risk of breast cancer in female carriers. However, genetic testing frequently reveals missense variants of uncertain significance (VUS) for which the impact on protein function and cancer risk are unclear. Here we assay 84% of all possible missense variants in 11 out of 13 PALB2 exons using site-saturation functional screens with PARP inhibitor sensitivity as a readout for HR. These exons encode the coiled-coil and WD40 domains, which we identify as the minimal regions required for HR. Furthermore, we reveal the functional impact of 6718 missense variants, classifying 3904 variants as functional (58%), 2422 as intermediate (36%), and 392 as damaging (6%). A burden-type analysis shows that damaging missense variants in PALB2 are associated with a significantly increased risk of breast cancer, similar to that observed for truncating variants. These results will be valuable for the classification of PALB2 missense VUS and clinical management of carriers.

> **中文摘要：**
> PALB2 的功能缺失变异会导致同源重组 (HR) 介导的 DNA 损伤修复缺陷，从而增加女性携带者患乳腺癌的风险。然而，基因检测经常发现意义不明的错义变异 (VUS)，其对蛋白质功能和癌症风险的影响尚不明确。在本研究中，我们利用饱和位点功能筛选，以 PARP 抑制剂敏感性作为 HR 的读数，检测了 PALB2 13 个外显子中 11 个外显子内 84% 的所有可能错义变异。这些外显子编码了卷曲螺旋 (coiled-coil) 和 WD40 结构域，我们将其鉴定为 HR 所需的最小区域。此外，我们揭示了 6718 个错义变异的功能影响，将 3904 个变异分类为功能性 (58%)，2422 个分类为中间型 (36%)，392 个分类为损伤性 (6%)。负担分析显示，PALB2 中的损伤性错义变异与乳腺癌风险显著增加相关，其风险程度与观察到的截短变异相似。这些结果对于 PALB2 错义 VUS 的分类和携带者的临床管理具有重要价值。

### 第二部分 AI 大师评价

本研究通过高通量饱和位点功能筛选技术，对 PALB2 基因关键结构域的数千个错义变异进行了系统性功能绘图，极大地扩展了临床 VUS 的功能注释。研究不仅明确了 HR 修复所需的核心结构域，还通过负担分析证实了损伤性错义变异的致病风险等同于截短变异。这一成果为乳腺癌易感基因的精准遗传咨询和临床决策提供了强有力的数据支撑，体现了功能基因组学在精准医学中的重要应用价值。

---

## 38. 2026年欧洲癌症死亡率预测：女性肺癌死亡率趋于平稳

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554652)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41554652
**DOI：** 10.1016/j.annonc.2025.12.005

### 第一部分 原文与翻译

**英文原标题：** European cancer mortality predictions for the year 2026: the levelling of female lung cancer mortality.

> **英文摘要：**
> BACKGROUND: We provided updated cancer mortality estimates for 2026 in the European Union (EU) and its five most populous countries, with a focus on lung cancer. MATERIALS AND METHODS: Cancer death certifications and population data were obtained from the World Health Organization and United Nations databases. For the EU, France, Germany, Italy, Poland, Spain, and the UK, we derived data for all cancers combined and major cancer sites since 1970. Linear regression models, based on the most recent age-specific trends identified by Poisson joinpoint regression, were used to estimate deaths in 2026. The number of averted deaths between 1989 and 2026 was computed by applying the 1988 peak rate to subsequent populations. RESULTS: For 2026, we estimated ∼1 230 000 EU cancer deaths, corresponding to age-standardised rates of 114.1/100 000 males (-7.8% versus 2020-2022) and 74.7/100 000 females (-5.9%). In the EU countries and the whole EU, favourable trends are predicted for most major cancers, except female pancreatic cancer. In the UK, predicted rates are also favourable, except female colorectal cancer. Lung cancer mortality continues to decrease markedly among males, while we predicted a levelling off of rates, around 12.5/100 000, among females in all considered countries and the whole of EU, except for Spain (+2.4%). Among females, lung cancer mortality declines are confined to those aged <65 years, while unfavourable trends continued in older age groups. Around 7.3 (5.0 in males, 2.3 in females) million total cancer deaths have been avoided in the EU since the peak observed in 1988. The corresponding figure for lung cancer is 1.8 million among males, while no averted deaths were recorded among females. CONCLUSION: Lung cancer mortality predictions for 2026 indicate a levelling off among EU females, with age- and country-specific differences. Mortality trends in ASRs for most cancers remain favourable in the EU and the UK, though the absolute number of cancer deaths is not declining due to population ageing.

> **中文摘要：**
> 【背景】我们提供了欧盟（EU）及其五个最具人口的国家2026年癌症死亡率的最新估算值，重点关注肺癌。【材料与方法】癌症死亡证明和人口数据来源于世界卫生组织和联合国数据库。针对欧盟、法国、德国、意大利、波兰、西班牙和英国，我们获取了自1970年以来所有癌症综合及主要癌症部位的数据。基于通过泊松连接点回归确定的最新年龄特异性趋势，使用线性回归模型估算2026年的死亡人数。通过将1988年的峰值率应用于后续人口，计算了1989年至2026年间避免的死亡人数。【结果】预计2026年欧盟癌症死亡人数约为1,230,000人，对应的男性年龄标准化率为114.1/10万（较2020-2022年下降7.8%），女性为74.7/10万（下降5.9%）。在欧盟各国及整个欧盟范围内，除女性胰腺癌外，大多数主要癌症预计均呈现向好趋势。在英国，除女性结直肠癌外，预测死亡率也较为乐观。男性肺癌死亡率继续显著下降，而在除西班牙（+2.4%）以外的所有研究国家及整个欧盟，女性肺癌死亡率预计将趋于平稳，维持在12.5/10万左右。在女性中，肺癌死亡率的下降仅限于65岁以下人群，而高年龄组仍呈现增长趋势。自1988年观察到峰值以来，欧盟共避免了约730万例癌症死亡（男性500万，女性230万）。肺癌的相关数据为男性避免180万例，而女性则没有记录到避免的死亡。【结论】2026年肺癌死亡率预测显示欧盟女性死亡率趋于平稳，且存在年龄和国家间的差异。尽管由于人口老龄化，癌症死亡的绝对人数并未下降，但欧盟和英国大多数癌症的年龄标准化死亡率趋势依然保持良好。

### 第二部分 AI 大师评价

本研究通过结合WHO与联合国数据库，利用高级统计模型对2026年欧洲癌症死亡趋势进行了精细化预测。核心发现是欧盟女性肺癌死亡率在经历长期上升后首次显现平稳信号，标志着控烟等公共卫生干预在女性群体中初见成效。研究不仅量化了自1988年以来数百万例因防控措施避免的死亡，也揭示了人口老龄化带来的巨大挑战。其主要创新点在于对肺癌死亡率拐点的捕捉，而局限性在于研究主要基于历史趋势外推，未充分考虑未来创新疗法对死亡率可能的剧烈干预效应。

---

## 39. 人口统计学、临床及饮食因素与炎症性肠病复发之间的关联：克罗恩病和结肠炎环境因素预后效应（PREdiCCt）前瞻性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41554630)
**期刊：** Gut
**PMID：** 41554630
**DOI：** 10.1136/gutjnl-2025-337846

### 第一部分 原文与翻译

**英文原标题：** Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study.

> **英文摘要：**
> BACKGROUND: IBD is characterised by recurrent flares, but evidence on whether modifiable dietary factors influence flare risk is limited.
> 
> OBJECTIVE: The PREdiCCt study was designed to examine demographic, clinical and dietary factors associated with disease flare among patients with IBD in self-reported remission.
> 
> DESIGN: Multicentre, prospective cohort study conducted across 47 UK centres. Patients with Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBDU) in self-reported remission were prospectively followed up. The baseline diet was assessed using a validated food frequency questionnaire. The primary outcome was time to patient-reported flare (captured by monthly IBD-Control) and objective flare (clinical flare plus C-reactive protein >5 mg/L and/or faecal calprotectin (FC) >250 µg/g with treatment escalation). Associations were evaluated using Cox frailty models adjusted for demographic, clinical and biochemical variables, including baseline FC.
> 
> RESULTS: Between November 2016 and March 2020, 2629 participants (1370 CD; 1259 UC/IBDU) were enrolled and followed up for a median of 4.1 years (IQR 3.0-5.0). Baseline FC was strongly associated with patient-reported flares (FC ≥250 µg/g: adjusted HR (aHR) 2.22; FC 50-250 µg/g: aHR 1.52 (reference <50 µg/g)) and objective flares (FC ≥250 µg/g: aHR 3.25; FC 50-250 µg/g: aHR 1.98). In UC, higher total meat intake was associated with increased risk of objective flares (highest versus lowest quartile: aHR 1.95, 95% CI 1.07 to 3.56). No consistent associations were observed for ultraprocessed foods, fibre or polyunsaturated fatty acids and flare.
> 
> CONCLUSION: Higher habitual meat intake was associated with increased risk of objective flare in UC, suggesting diet may contribute to flare susceptibility in specific patient groups.

> **中文摘要：**
> 背景：炎症性肠病（IBD）以反复发作为特征，但关于可干预的饮食因素是否影响发作风险的证据有限。
> 
> 目的：PREdiCCt研究旨在探讨处于自我报告缓解期的IBD患者中，与疾病复发相关的人口统计学、临床和饮食因素。
> 
> 设计：在英国47个中心开展的多中心、前瞻性队列研究。对处于自我报告缓解期的克罗恩病（CD）、溃疡性结肠炎（UC）或未分类IBD（IBDU）患者进行前瞻性随访。基线饮食通过经过验证的食物频数问卷进行评估。主要结局是患者报告复发的时间（通过每月IBD-Control量表捕获）和客观复发（指临床复发伴C反应蛋白 >5 mg/L 和/或粪便钙卫蛋白 (FC) >250 µg/g 且伴有治疗升级）。使用Cox脆弱模型评估关联性，并对人口统计学、临床和生化变量（包括基线FC）进行了调整。
> 
> 结果：2016年11月至2020年3月期间，共招募2629名受试者（1370名CD；1259名UC/IBDU），中位随访时间为4.1年（IQR 3.0-5.0）。基线FC与患者报告的复发（FC ≥250 µg/g：调整后风险比 (aHR) 2.22；FC 50-250 µg/g：aHR 1.52（参考值 <50 µg/g））以及客观复发（FC ≥250 µg/g：aHR 3.25；FC 50-250 µg/g：aHR 1.98）强相关。在UC患者中，较高的总肉类摄入量与客观复发风险增加相关（最高四分位数与最低四分位数相比：aHR 1.95, 95% CI 1.07-3.56）。在超加工食品、纤维或多不饱和脂肪酸与复发之间未观察到一致的关联。
> 
> 结论：较高的习惯性肉类摄入量与UC的客观复发风险增加相关，这表明饮食可能在特定患者群体的复发易感性中发挥作用。

### 第二部分 AI 大师评价

这项大规模前瞻性队列研究（PREdiCCt）通过对2629名IBD患者长达4.1年的随访，深入探讨了饮食与疾病复发的长期关联。研究的一大亮点是结合了患者自我报告和客观生化指标（如粪便钙卫蛋白）双重终点，显著提升了结果的临床说服力。研究发现肉类摄入是UC复发的风险因素，而令人意外地推翻了纤维和超加工食品与复发的必然联系，这对现行的IBD膳食指导具有重要的修正意义。局限性在于饮食评估依赖于自填问卷，可能存在一定的报告偏倚。

---

速递结束，祝您工作愉快！